{"DataElement":{"publicId":"3188868","version":"2","preferredName":"Person Gynecologic Oncology Group Other Clinical Study Randomization Clinical Trial Eligibility Criteria Protocol Treatment Arm Assignment Type","preferredDefinition":"Information related a person's randomization on another clinical trial sponsored by the Gynecologic Oncology Group as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial, and the treatment arm assignment as indicated by the protocol.","longName":"3188774v1.0:2185490v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3188774","version":"1","preferredName":"Person Gynecologic Oncology Group Other Clinical Study Randomization Clinical Trial Eligibility Criteria","preferredDefinition":"information related a person's randomization on another clinical trial sponsored by the Gynecologic Oncology Group as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3188772v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3188772","version":"1","preferredName":"Gynecologic Oncology Group Other Clinical Study Randomization Clinical Trial Eligibility Criteria","preferredDefinition":"The Gynecologic Oncology Group (GOG) is a non-profit NCI-supported organization headquartered in Philadelphia, PA, with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. Approximately 45 individual clinical trials are active at any one time within GOG.:Different than the one(s) previously specified or mentioned.:Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. :The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3188772v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gynecologic Oncology Group","conceptCode":"C25521","definition":"A non-profit NCI-supported organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. Approximately 45 individual clinical trials are active at any one time within GOG.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Randomization","conceptCode":"C25196","definition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B77993E-64B2-3182-E040-BB89AD430257","latestVersionIndicator":"Yes","beginDate":"2011-02-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-04","modifiedBy":"ONEDATA","dateModified":"2011-02-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B77993E-64C3-3182-E040-BB89AD430257","latestVersionIndicator":"Yes","beginDate":"2011-02-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2185490","version":"1.1","preferredName":"Protocol Treatment Arm Assignment Type","preferredDefinition":"the treatment arm assignment as indicated by the protocol.","longName":"PROT_TX_ARM_ASSIG_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Radiation therapy","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2559934","version":"1","preferredName":"Radiation Therapy","longName":"2559934","preferredDefinition":"use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B72B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"REEVESD","dateModified":"2009-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8223-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Docetaxel/Gemcitabine - AC","valueDescription":"Docetaxel and Gemcitabine followed by Doxorubicin and Cyclophosphamide","ValueMeaning":{"publicId":"2580486","version":"1","preferredName":"Docetaxel and Gemcitabine followed by Doxorubicin and Cyclophosphamide","longName":"2580486","preferredDefinition":"Docetaxel and Gemcitabine followed by Doxorubicin and Cyclophosphamide (AC)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0773-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-11","modifiedBy":"ALAIS","dateModified":"2006-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-822D-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Docetaxel/Capecitabine + Bevacizumab- AC + Bevacizumab","valueDescription":"Docetaxel, Gemcitabine and Bevacizumab followed by Doxorubicin, Cyclophosphamide and Bevacizumab","ValueMeaning":{"publicId":"2580489","version":"1","preferredName":"Docetaxel, Gemcitabine and Bevacizumab followed by Doxorubicin, Cyclophosphamide and Bevacizumab","longName":"2580489","preferredDefinition":"Docetaxel, Gemcitabine and Bevacizumab followed by Doxorubicin, Cyclophosphamide (AC) and Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0776-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-11","modifiedBy":"ALAIS","dateModified":"2006-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8237-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Docetaxel - AC","valueDescription":"Docetaxel followed by Doxorubicin and Cyclophosphamide","ValueMeaning":{"publicId":"2580483","version":"1","preferredName":"Docetaxel followed by Doxorubicin and Cyclophosphamide","longName":"2580483","preferredDefinition":"Docetaxel followed by Doxorubicin and Cyclophosphamide (AC)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0770-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-11","modifiedBy":"ALAIS","dateModified":"2006-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8241-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Docetaxel + Bevacizumab - AC + Bevacizumab","valueDescription":"Docetaxel and Bevacizumab followed by Doxorubicin, Cyclophosphamide and Bevacizumab","ValueMeaning":{"publicId":"2580487","version":"1","preferredName":"Docetaxel and Bevacizumab followed by Doxorubicin, Cyclophosphamide and Bevacizumab","longName":"2580487","preferredDefinition":"Docetaxel and Bevacizumab followed by Doxorubicin, Cyclophosphamide (AC) and Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0774-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-11","modifiedBy":"ALAIS","dateModified":"2006-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-824B-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"DD AC - P","valueDescription":"Doxorubicin, cyclophosphamide followed by paclitaxel (DD AC - P)","ValueMeaning":{"publicId":"2569618","version":"1","preferredName":"Doxorubicin, cyclophosphamide followed by paclitaxel (DD AC - P)","longName":"2569618","preferredDefinition":"Doxorubicin, cyclophosphamide followed by paclitaxel (DD AC - P)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DCFF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-05-19","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8255-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"DD AC - PG","valueDescription":"Doxorubicin, cyclophosphamide followed by paclitaxel and gemcitabine (DD AC - PG)","ValueMeaning":{"publicId":"2569619","version":"1","preferredName":"Doxorubicin, cyclophosphamide followed by paclitaxel and gemcitabine (DD AC - PG)","longName":"2569619","preferredDefinition":"Doxorubicin, cyclophosphamide followed by paclitaxel and gemcitabine (DD AC - PG)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DD00-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-05-19","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-825F-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A = Paclitaxel + Bevacizumab","valueDescription":"Arm A = Paclitaxel + Bevacizumab","ValueMeaning":{"publicId":"2766511","version":"1","preferredName":"Arm A = Paclitaxel + Bevacizumab","longName":"2766511","preferredDefinition":"Arm A = Paclitaxel + Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52152C61-1F11-29D7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8269-3460-E053-4EBD850A1FCF","beginDate":"2008-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B = Nab-Paclitaxel + Bevacizumab","valueDescription":"Arm B = Nab-Paclitaxel + Bevacizumab","ValueMeaning":{"publicId":"2766512","version":"1","preferredName":"Arm B = Nab-Paclitaxel + Bevacizumab","longName":"2766512","preferredDefinition":"Arm B = Nab-Paclitaxel + Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52152EC9-BCEB-29D1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8273-3460-E053-4EBD850A1FCF","beginDate":"2008-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm C = Ixabepilone + Bevacizumab","valueDescription":"Arm C = Ixabepilone + Bevacizumab","ValueMeaning":{"publicId":"2766513","version":"1","preferredName":"Arm C = Ixabepilone + Bevacizumab","longName":"2766513","preferredDefinition":"Arm C = Ixabepilone + Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52152EC9-BCFB-29D1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-827D-3460-E053-4EBD850A1FCF","beginDate":"2008-07-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"A","valueDescription":"Capecitabine + Lapatinib","ValueMeaning":{"publicId":"2779060","version":"1","preferredName":"Capecitabine + Lapatinib","longName":"2779060","preferredDefinition":"Capecitabine + Lapatinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"559F1F10-E68F-0216-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8287-3460-E053-4EBD850A1FCF","beginDate":"2008-08-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"B","valueDescription":"IMC-A12 + Capecitabine + Lapatinib","ValueMeaning":{"publicId":"2779061","version":"1","preferredName":"IMC-A12 + Capecitabine + Lapatinib","longName":"2779061","preferredDefinition":"IMC-A12 + Capecitabine + Lapatinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"559F5144-D5DF-110D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8291-3460-E053-4EBD850A1FCF","beginDate":"2008-08-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Bevacizumab alone","valueDescription":"Bevacizumab alone","ValueMeaning":{"publicId":"2569366","version":"1","preferredName":"Bevacizumab alone","longName":"2569366","preferredDefinition":"Bevacizumab alone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC03-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-04-23","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-829B-3460-E053-4EBD850A1FCF","beginDate":"2008-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Bevacizumab and Irinotecan","valueDescription":"Bevacizumab and Irinotecan","ValueMeaning":{"publicId":"2800764","version":"1","preferredName":"Bevacizumab and Irinotecan","longName":"2800764","preferredDefinition":"Bevacizumab and Irinotecan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BA8DEB0-83B9-6486-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82A5-3460-E053-4EBD850A1FCF","beginDate":"2008-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Bevacizumab and TMZ salvage","valueDescription":"Bevacizumab and TMZ salvage","ValueMeaning":{"publicId":"2800765","version":"1","preferredName":"Bevacizumab and TMZ salvage","longName":"2800765","preferredDefinition":"Bevacizumab and TMZ salvage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BA8E0FE-806B-71EE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82AF-3460-E053-4EBD850A1FCF","beginDate":"2008-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Patient not randomized for other reason","valueDescription":"Patient not randomized for other reason","ValueMeaning":{"publicId":"2822301","version":"1","preferredName":"Patient not randomized for other reason","longName":"2822301","preferredDefinition":"Patient not randomized for other reason","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FEA9626-75BE-D429-E040-BB89AD433C56","latestVersionIndicator":"Yes","beginDate":"2009-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82B9-3460-E053-4EBD850A1FCF","beginDate":"2009-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Patient not randomized due to ineligibility","valueDescription":"Patient not randomized due to ineligibility","ValueMeaning":{"publicId":"2822302","version":"1","preferredName":"Patient not randomized due to ineligibility","longName":"2822302","preferredDefinition":"Patient not randomized due to ineligibility","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FEA9626-75E3-D429-E040-BB89AD433C56","latestVersionIndicator":"Yes","beginDate":"2009-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82C3-3460-E053-4EBD850A1FCF","beginDate":"2009-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Patient refused assigned treatment after randomization","valueDescription":"Patient refused assigned treatment after randomization","ValueMeaning":{"publicId":"2822303","version":"1","preferredName":"Patient refused assigned treatment after randomization","longName":"2822303","preferredDefinition":"Patient refused assigned treatment after randomization","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FEA9626-7608-D429-E040-BB89AD433C56","latestVersionIndicator":"Yes","beginDate":"2009-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82CD-3460-E053-4EBD850A1FCF","beginDate":"2009-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Patient refused to be randomized","valueDescription":"Patient refused to be randomized","ValueMeaning":{"publicId":"2822304","version":"1","preferredName":"Patient refused to be randomized","longName":"2822304","preferredDefinition":"Patient refused to be randomized","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FEA9626-762D-D429-E040-BB89AD433C56","latestVersionIndicator":"Yes","beginDate":"2009-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82D7-3460-E053-4EBD850A1FCF","beginDate":"2009-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Randomized to observation","valueDescription":"Randomized to observation","ValueMeaning":{"publicId":"2822305","version":"1","preferredName":"Randomized to observation","longName":"2822305","preferredDefinition":"Randomized to observation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FEA9626-7652-D429-E040-BB89AD433C56","latestVersionIndicator":"Yes","beginDate":"2009-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82E1-3460-E053-4EBD850A1FCF","beginDate":"2009-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Regimen 3: Gemcitabine and Cisplatin","valueDescription":"Regimen 3: Gemcitabine and Cisplatin","ValueMeaning":{"publicId":"2822306","version":"1","preferredName":"Regimen 3: Gemcitabine and Cisplatin","longName":"2822306","preferredDefinition":"Regimen 3: Gemcitabine and Cisplatin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FEA9626-7677-D429-E040-BB89AD433C56","latestVersionIndicator":"Yes","beginDate":"2009-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82EB-3460-E053-4EBD850A1FCF","beginDate":"2009-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Regimen 2: Docetaxel and Cisplatin","valueDescription":"Regimen 2: Docetaxel and Cisplatin","ValueMeaning":{"publicId":"2822307","version":"1","preferredName":"Regimen 2: Docetaxel and Cisplatin","longName":"2822307","preferredDefinition":"Regimen 2: Docetaxel and Cisplatin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FEA9626-769C-D429-E040-BB89AD433C56","latestVersionIndicator":"Yes","beginDate":"2009-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82F5-3460-E053-4EBD850A1FCF","beginDate":"2009-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Regimen 1: Vinorelbine and Cisplatin","valueDescription":"Regimen 1: Vinorelbine and Cisplatin","ValueMeaning":{"publicId":"2822308","version":"1","preferredName":"Regimen 1: Vinorelbine and Cisplatin","longName":"2822308","preferredDefinition":"Regimen 1: Vinorelbine and Cisplatin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FEA9626-76C1-D429-E040-BB89AD433C56","latestVersionIndicator":"Yes","beginDate":"2009-01-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-82FF-3460-E053-4EBD850A1FCF","beginDate":"2009-01-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Bevacizumab/placebo","valueDescription":"Bevacizumab/placebo","ValueMeaning":{"publicId":"2800857","version":"1","preferredName":"Bevacizumab/placebo","longName":"2800857","preferredDefinition":"Bevacizumab/placebo","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAACBEE-CAD9-57DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8309-3460-E053-4EBD850A1FCF","beginDate":"2008-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"TMZ","valueDescription":"TMZ","ValueMeaning":{"publicId":"2800858","version":"1","preferredName":"TMZ","longName":"2800858","preferredDefinition":"Temozolomide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAAD3F8-F6C7-57D2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8313-3460-E053-4EBD850A1FCF","beginDate":"2008-11-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B: Bevacizumab + Chemotherapy","valueDescription":"Arm B: Bevacizumab + Chemotherapy","ValueMeaning":{"publicId":"2815813","version":"1","preferredName":"Arm B: Bevacizumab + Chemotherapy","longName":"2815813","preferredDefinition":"Arm B: Bevacizumab + Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5DDE3F72-CE76-F14F-E040-BB89A6436EB4","latestVersionIndicator":"Yes","beginDate":"2008-12-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-12-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-831D-3460-E053-4EBD850A1FCF","beginDate":"2008-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A: Cetuximab + Chemotherapy","valueDescription":"Arm A: Cetuximab + Chemotherapy","ValueMeaning":{"publicId":"2815814","version":"1","preferredName":"Arm A: Cetuximab + Chemotherapy","longName":"2815814","preferredDefinition":"Arm A: Cetuximab + Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5DDE3F72-CE9B-F14F-E040-BB89A6436EB4","latestVersionIndicator":"Yes","beginDate":"2008-12-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-12-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8327-3460-E053-4EBD850A1FCF","beginDate":"2008-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Carboplatin/Paclitaxel/Bevacizumab followed by Bevacizumab","valueDescription":"Carboplatin/Paclitaxel/Bevacizumab followed by Bevacizumab","ValueMeaning":{"publicId":"2866038","version":"1","preferredName":"Carboplatin/Paclitaxel/Bevacizumab followed by Bevacizumab","longName":"2866038","preferredDefinition":"Carboplatin/Paclitaxel/Bevacizumab followed by Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68B4278A-ED61-DCEF-E040-BB89AD4366B3","latestVersionIndicator":"Yes","beginDate":"2009-04-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8331-3460-E053-4EBD850A1FCF","beginDate":"2009-04-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Carboplatin/Paclitaxel/Cetuximab/Bevacizumab followed by Bevacizumab/Cetuximab","valueDescription":"Carboplatin/Paclitaxel/Cetuximab/Bevacizumab followed by Bevacizumab/Cetuximab","ValueMeaning":{"publicId":"2866040","version":"1","preferredName":"Carboplatin/Paclitaxel/Cetuximab/Bevacizumab followed by Bevacizumab/Cetuximab","longName":"2866040","preferredDefinition":"Carboplatin/Paclitaxel/Cetuximab/Bevacizumab followed by Bevacizumab/Cetuximab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68B42C07-8107-9E38-E040-BB89AD437090","latestVersionIndicator":"Yes","beginDate":"2009-04-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-833B-3460-E053-4EBD850A1FCF","beginDate":"2009-04-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Carboplatin/Paclitaxel/Cetuximab followed by Cetuximab","valueDescription":"Carboplatin/Paclitaxel/Cetuximab followed by Cetuximab","ValueMeaning":{"publicId":"2866041","version":"1","preferredName":"Carboplatin/Paclitaxel/Cetuximab followed by Cetuximab","longName":"2866041","preferredDefinition":"Carboplatin/Paclitaxel/Cetuximab followed by Cetuximab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68B42D8F-1A31-E87C-E040-BB89AD435916","latestVersionIndicator":"Yes","beginDate":"2009-04-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8345-3460-E053-4EBD850A1FCF","beginDate":"2009-04-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Carboplatin/Paclitaxel","valueDescription":"Carboplatin/Paclitaxel","ValueMeaning":{"publicId":"2866039","version":"1","preferredName":"Carboplatin/Paclitaxel","longName":"2866039","preferredDefinition":"Carboplatin/Paclitaxel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68B42928-9BCB-02C7-E040-BB89AD436A53","latestVersionIndicator":"Yes","beginDate":"2009-04-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-04-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-834F-3460-E053-4EBD850A1FCF","beginDate":"2009-04-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Systemic Therapy After Crossover","valueDescription":"Systemic Therapy After Crossover","ValueMeaning":{"publicId":"2880149","version":"1","preferredName":"Systemic Therapy After Crossover","longName":"2880149","preferredDefinition":"Systemic Therapy After Crossover","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A5ADF78-4C1D-4AC8-E040-BB89AD436F01","latestVersionIndicator":"Yes","beginDate":"2009-05-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-05-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8359-3460-E053-4EBD850A1FCF","beginDate":"2009-05-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Combined modality therapy ","valueDescription":"Combined modality therapy ","ValueMeaning":{"publicId":"2834595","version":"1","preferredName":"Combined modality therapy ","longName":"2834595","preferredDefinition":"Combined modality therapy ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6242DF16-2D62-44A1-E040-BB89AD436C76","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8363-3460-E053-4EBD850A1FCF","beginDate":"2009-02-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Systemic Therapy prior to cross-over ","valueDescription":"Systemic Therapy prior to cross-over ","ValueMeaning":{"publicId":"2834596","version":"1","preferredName":"Systemic Therapy prior to cross-over ","longName":"2834596","preferredDefinition":"Systemic Therapy prior to cross-over ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6242E0AB-4F9A-E2BC-E040-BB89AD437219","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-836D-3460-E053-4EBD850A1FCF","beginDate":"2009-02-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Best systemic Therapy after cross-over ","valueDescription":"Best systemic Therapy after cross-over ","ValueMeaning":{"publicId":"2834597","version":"1","preferredName":"Best systemic Therapy after cross-over ","longName":"2834597","preferredDefinition":"Best systemic Therapy after cross-over ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6242E1EB-D91B-C672-E040-BB89AD436C78","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8377-3460-E053-4EBD850A1FCF","beginDate":"2009-02-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A: Doxorubicin plus Sorafenib","valueDescription":"Arm A: Doxorubicin plus Sorafenib","ValueMeaning":{"publicId":"2946389","version":"1","preferredName":"Arm A: Doxorubicin plus Sorafenib","longName":"2946389","preferredDefinition":"Arm A: Doxorubicin plus Sorafenib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7472354A-1900-09C7-E040-BB89AD43621C","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8381-3460-E053-4EBD850A1FCF","beginDate":"2009-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B: Sorafenib","valueDescription":"Arm B: Sorafenib","ValueMeaning":{"publicId":"2946390","version":"1","preferredName":"Arm B: Sorafenib","longName":"2946390","preferredDefinition":"Arm B: Sorafenib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74723744-B7A7-4C1B-E040-BB89AD433866","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-838B-3460-E053-4EBD850A1FCF","beginDate":"2009-09-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"RA","valueDescription":"Restoration Arm","ValueMeaning":{"publicId":"2921777","version":"1","preferredName":"Restoration Arm","longName":"2921777","preferredDefinition":"Restoration Arm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F429278-3EE4-A93D-E040-BB89AD431871","latestVersionIndicator":"Yes","beginDate":"2009-07-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8395-3460-E053-4EBD850A1FCF","beginDate":"2009-07-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SA","valueDescription":"Sealant Arm","ValueMeaning":{"publicId":"2921778","version":"1","preferredName":"Sealant Arm","longName":"2921778","preferredDefinition":"Sealant Arm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F429278-3F07-A93D-E040-BB89AD431871","latestVersionIndicator":"Yes","beginDate":"2009-07-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-839F-3460-E053-4EBD850A1FCF","beginDate":"2009-07-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"DA","valueDescription":"Dentifrice Arm","ValueMeaning":{"publicId":"2921779","version":"1","preferredName":"Dentifrice Arm","longName":"2921779","preferredDefinition":"Dentifrice Arm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F429278-3F2A-A93D-E040-BB89AD431871","latestVersionIndicator":"Yes","beginDate":"2009-07-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83A9-3460-E053-4EBD850A1FCF","beginDate":"2009-07-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"A) Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX)","valueDescription":"A) Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX)","ValueMeaning":{"publicId":"2932355","version":"1","preferredName":"A) Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX)","longName":"2932355","preferredDefinition":"A) Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70F59428-0B70-298C-E040-BB89AD431C2D","latestVersionIndicator":"Yes","beginDate":"2009-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83B3-3460-E053-4EBD850A1FCF","beginDate":"2009-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"D) Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX) + C225","valueDescription":"D) Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX) + C225","ValueMeaning":{"publicId":"2932356","version":"1","preferredName":"D) Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX) + C225","longName":"2932356","preferredDefinition":"D) Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX) + C225","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70F5988B-2248-3BC5-E040-BB89AD431E00","latestVersionIndicator":"Yes","beginDate":"2009-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83BD-3460-E053-4EBD850A1FCF","beginDate":"2009-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A or D","valueDescription":"Arm A or D","ValueMeaning":{"publicId":"2932220","version":"1","preferredName":"Arm A or D","longName":"2932220","preferredDefinition":"Arm A or D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70E32551-DE00-6BC3-E040-BB89AD430B2D","latestVersionIndicator":"Yes","beginDate":"2009-08-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83C7-3460-E053-4EBD850A1FCF","beginDate":"2009-08-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Pre-randomization","valueDescription":"Pre-randomization","ValueMeaning":{"publicId":"2932714","version":"1","preferredName":"Pre-randomization","longName":"2932714","preferredDefinition":"Pre-randomization","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"710A3976-1F39-270E-E040-BB89AD4322B4","latestVersionIndicator":"Yes","beginDate":"2009-08-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83D1-3460-E053-4EBD850A1FCF","beginDate":"2009-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B: Limited Resection","valueDescription":"Arm B: Limited Resection","ValueMeaning":{"publicId":"2916954","version":"1","preferredName":"Arm B: Limited Resection","longName":"2916954","preferredDefinition":"Arm B: Limited Resection","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E4C44DC-203E-32E2-E040-BB89AD4321BB","latestVersionIndicator":"Yes","beginDate":"2009-07-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83DB-3460-E053-4EBD850A1FCF","beginDate":"2009-07-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A: Lobectomy","valueDescription":"Arm A: Lobectomy","ValueMeaning":{"publicId":"2916955","version":"1","preferredName":"Arm A: Lobectomy","longName":"2916955","preferredDefinition":"Arm A: Lobectomy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E4C44DC-2061-32E2-E040-BB89AD4321BB","latestVersionIndicator":"Yes","beginDate":"2009-07-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83E5-3460-E053-4EBD850A1FCF","beginDate":"2009-07-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"G) Locally-Directed Therapy","valueDescription":"Locally-Directed Therapy","ValueMeaning":{"publicId":"2932357","version":"1","preferredName":"Locally-Directed Therapy","longName":"2932357","preferredDefinition":"Locally-Directed Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70F59B45-C86E-FA49-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2009-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83EF-3460-E053-4EBD850A1FCF","beginDate":"2009-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Locally-Directed Therapy","valueDescription":"Locally-Directed Therapy","ValueMeaning":{"publicId":"2932357","version":"1","preferredName":"Locally-Directed Therapy","longName":"2932357","preferredDefinition":"Locally-Directed Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70F59B45-C86E-FA49-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2009-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-83F9-3460-E053-4EBD850A1FCF","beginDate":"2009-08-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm G","valueDescription":"Arm G","ValueMeaning":{"publicId":"2932221","version":"1","preferredName":"Arm G","longName":"2932221","preferredDefinition":"Arm G","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70E3270B-C41D-070B-E040-BB89AD430AFD","latestVersionIndicator":"Yes","beginDate":"2009-08-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8403-3460-E053-4EBD850A1FCF","beginDate":"2009-08-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2: Endocrine therapy alone","valueDescription":"Arm 2: Endocrine therapy only","ValueMeaning":{"publicId":"3144115","version":"1","preferredName":"Arm 2: Endocrine therapy only","longName":"3144115","preferredDefinition":"Arm 2: Endocrine therapy only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"916B7C89-82E3-C36B-E040-BB89AD431D09","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-840D-3460-E053-4EBD850A1FCF","beginDate":"2010-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"A) Vorinostat* + Temozolomide --> Vorinostat + Temozolomide","valueDescription":"Vorinostat* + Temozolomide --> Vorinostat + Temozolomide","ValueMeaning":{"publicId":"3015355","version":"1","preferredName":"Vorinostat* + Temozolomide --> Vorinostat + Temozolomide","longName":"3015355","preferredDefinition":"Vorinostat* + Temozolomide --> Vorinostat + Temozolomide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"804DE5CB-58AE-5EDB-E040-BB89AD4333D2","latestVersionIndicator":"Yes","beginDate":"2010-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8417-3460-E053-4EBD850A1FCF","beginDate":"2010-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Sequential Chemotherapy","valueDescription":"Sequential Chemotherapy","ValueMeaning":{"publicId":"3057577","version":"1","preferredName":"Sequential Chemotherapy","longName":"3057577","preferredDefinition":"Sequential Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"840AD15F-60C2-B8C8-E040-BB89AD436B44","latestVersionIndicator":"Yes","beginDate":"2010-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8421-3460-E053-4EBD850A1FCF","beginDate":"2010-04-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2: Endocrine therapy only","valueDescription":"Arm 2: Endocrine therapy only","ValueMeaning":{"publicId":"3144115","version":"1","preferredName":"Arm 2: Endocrine therapy only","longName":"3144115","preferredDefinition":"Arm 2: Endocrine therapy only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"916B7C89-82E3-C36B-E040-BB89AD431D09","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-842B-3460-E053-4EBD850A1FCF","beginDate":"2010-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1: Chemotherapy + endocrine therapy","valueDescription":"Arm 1: Chemotherapy + endocrine therapy","ValueMeaning":{"publicId":"3144116","version":"1","preferredName":"Arm 1: Chemotherapy + endocrine therapy","longName":"3144116","preferredDefinition":"Arm 1: Chemotherapy + endocrine therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"916B7C89-8306-C36B-E040-BB89AD431D09","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8435-3460-E053-4EBD850A1FCF","beginDate":"2010-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Sunitinib/Placebo","valueDescription":"Sunitinib Placebo","ValueMeaning":{"publicId":"3134354","version":"1","preferredName":"Sunitinib Placebo","longName":"3134354","preferredDefinition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.: An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib","conceptCode":"C71622","definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F391D7A-E9F3-2C4D-E040-BB89AD4302AD","latestVersionIndicator":"Yes","beginDate":"2010-09-01","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-09-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-843F-3460-E053-4EBD850A1FCF","beginDate":"2010-09-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"B) Fluoropyrimidine/oxaliplatin + bevacizumab","valueDescription":"B) Fluoropyrimidine/oxaliplatin + bevacizumab","ValueMeaning":{"publicId":"3151735","version":"1","preferredName":"B) Fluoropyrimidine/oxaliplatin + bevacizumab","longName":"3151735","preferredDefinition":"B) Fluoropyrimidine/oxaliplatin + bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92DF6874-FB10-81F7-E040-BB89AD43054C","latestVersionIndicator":"Yes","beginDate":"2010-10-18","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8449-3460-E053-4EBD850A1FCF","beginDate":"2010-10-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"A) Fluoropyrimidine + bevacizumab","valueDescription":"A) Fluoropyrimidine + bevacizumab","ValueMeaning":{"publicId":"3151736","version":"1","preferredName":"A) Fluoropyrimidine + bevacizumab","longName":"3151736","preferredDefinition":"A) Fluoropyrimidine + bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92DF6874-FB33-81F7-E040-BB89AD43054C","latestVersionIndicator":"Yes","beginDate":"2010-10-18","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8453-3460-E053-4EBD850A1FCF","beginDate":"2010-10-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"A) MK-2206 + TREANDA + RITUX","valueDescription":"A) MK-2206 + TREANDA + RITUX","ValueMeaning":{"publicId":"3233757","version":"1","preferredName":"A) MK-2206 + TREANDA + RITUX","longName":"3233757","preferredDefinition":"A) MK-2206 + TREANDA + RITUX","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A288803E-DA49-BB91-E040-BB89AD436A61","latestVersionIndicator":"Yes","beginDate":"2011-05-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-845D-3460-E053-4EBD850A1FCF","beginDate":"2011-05-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8467-3460-E053-4EBD850A1FCF","beginDate":"2011-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Ofatumumab 1000 mg","valueDescription":"Ofatumumab 1000 mg","ValueMeaning":{"publicId":"3210297","version":"1","preferredName":"Ofatumumab 1000 mg","longName":"3210297","preferredDefinition":"Ofatumumab 1000 mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F3E79A4-6955-31D2-E040-BB89AD434AF8","latestVersionIndicator":"Yes","beginDate":"2011-03-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-03-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8471-3460-E053-4EBD850A1FCF","beginDate":"2011-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Ofatumumab 500 mg","valueDescription":"Ofatumumab 500 mg","ValueMeaning":{"publicId":"3210298","version":"1","preferredName":"Ofatumumab 500 mg","longName":"3210298","preferredDefinition":"Ofatumumab 500 mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F3E79A4-6978-31D2-E040-BB89AD434AF8","latestVersionIndicator":"Yes","beginDate":"2011-03-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-03-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-847B-3460-E053-4EBD850A1FCF","beginDate":"2011-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"RAD001 + RCHOP","valueDescription":"RAD001 + RCHOP","ValueMeaning":{"publicId":"3210435","version":"1","preferredName":"RAD001 + RCHOP","longName":"3210435","preferredDefinition":"A) RAD001 + RCHOP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F40F621-6EE0-E1E3-E040-BB89AD431EEA","latestVersionIndicator":"Yes","beginDate":"2011-03-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-03-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8485-3460-E053-4EBD850A1FCF","beginDate":"2011-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"A) RAD001 + RCHOP","valueDescription":"RAD001 + RCHOP","ValueMeaning":{"publicId":"3210435","version":"1","preferredName":"RAD001 + RCHOP","longName":"3210435","preferredDefinition":"A) RAD001 + RCHOP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F40F621-6EE0-E1E3-E040-BB89AD431EEA","latestVersionIndicator":"Yes","beginDate":"2011-03-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-03-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-848F-3460-E053-4EBD850A1FCF","beginDate":"2011-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SBRT only","valueDescription":"Stereotactic Body Radiation Therapy only","ValueMeaning":{"publicId":"3181460","version":"1","preferredName":"Stereotactic Body Radiation Therapy only","longName":"3181460","preferredDefinition":"Stereotactic Body Radiation Therapy only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9932D78C-BAB9-314D-E040-BB89AD433966","latestVersionIndicator":"Yes","beginDate":"2011-01-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8499-3460-E053-4EBD850A1FCF","beginDate":"2011-01-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Surgery without brachytherapy","valueDescription":"Surgery without brachytherapy","ValueMeaning":{"publicId":"3181461","version":"1","preferredName":"Surgery without brachytherapy","longName":"3181461","preferredDefinition":"Surgery without brachytherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9932D78C-BADC-314D-E040-BB89AD433966","latestVersionIndicator":"Yes","beginDate":"2011-01-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84A3-3460-E053-4EBD850A1FCF","beginDate":"2011-01-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Surgery with brachytherapy","valueDescription":"Surgery with brachytherapy","ValueMeaning":{"publicId":"3181462","version":"1","preferredName":"Surgery with brachytherapy","longName":"3181462","preferredDefinition":"Surgery with brachytherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9932D78C-BAFF-314D-E040-BB89AD433966","latestVersionIndicator":"Yes","beginDate":"2011-01-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84AD-3460-E053-4EBD850A1FCF","beginDate":"2011-01-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Pre-Registration","valueDescription":"Preregistration","ValueMeaning":{"publicId":"2575817","version":"1","preferredName":"Preregistration","longName":"2575817","preferredDefinition":"Preregistration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F536-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-07-27","modifiedBy":"MAESKEB","dateModified":"2005-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84B7-3460-E053-4EBD850A1FCF","beginDate":"2011-04-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SRS","valueDescription":"Stereotactic Radiosurgery","ValueMeaning":{"publicId":"2578537","version":"1","preferredName":"Stereotactic Radiosurgery","longName":"2578537","preferredDefinition":"A type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. It is also being studied in the treatment of other types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stereotactic Radiosurgery","conceptCode":"C15358","definition":"A non-surgical procedure that was developed to deliver one or several maximum dose targeted radiation treatments for cancers in the brain or spine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFD6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-04-05","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84C1-3460-E053-4EBD850A1FCF","beginDate":"2011-04-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"WBRT","valueDescription":"Total-Body Irradiation","ValueMeaning":{"publicId":"3228419","version":"1","preferredName":"Total-Body Irradiation","longName":"3228419","preferredDefinition":"Radiation therapy to the entire body. Usually followed by bone marrow or peripheral stem cell transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16E86D8-A4DB-A34E-E040-BB89AD434C07","latestVersionIndicator":"Yes","beginDate":"2011-04-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84CB-3460-E053-4EBD850A1FCF","beginDate":"2011-04-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"AFP464","valueDescription":"AFP464","ValueMeaning":{"publicId":"3235720","version":"1","preferredName":"AFP464","longName":"3235720","preferredDefinition":"AFP464","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A37CAB6D-62BF-8E3C-E040-BB89AD432056","latestVersionIndicator":"Yes","beginDate":"2011-05-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84D5-3460-E053-4EBD850A1FCF","beginDate":"2011-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm C = Ixabepilone +/- Bevacizumab","valueDescription":"Arm C = Ixabepilone +/- Bevacizumab","ValueMeaning":{"publicId":"3187728","version":"1","preferredName":"Arm C = Ixabepilone +/- Bevacizumab","longName":"3187728","preferredDefinition":"Arm C = Ixabepilone +/- Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AEF897D-E424-105D-E040-BB89AD4361BA","latestVersionIndicator":"Yes","beginDate":"2011-01-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84DF-3460-E053-4EBD850A1FCF","beginDate":"2011-01-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B = Nab-Paclitaxel +/- Bevacizumab","valueDescription":"Arm B = Nab-Paclitaxel +/- Bevacizumab","ValueMeaning":{"publicId":"3187729","version":"1","preferredName":"Arm B = Nab-Paclitaxel +/- Bevacizumab","longName":"3187729","preferredDefinition":"Arm B = Nab-Paclitaxel +/- Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AEF897D-E447-105D-E040-BB89AD4361BA","latestVersionIndicator":"Yes","beginDate":"2011-01-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84E9-3460-E053-4EBD850A1FCF","beginDate":"2011-01-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A = Paclitaxel +/- Bevacizumab","valueDescription":"Arm A = Paclitaxel +/- Bevacizumab","ValueMeaning":{"publicId":"3187730","version":"1","preferredName":"Arm A = Paclitaxel +/- Bevacizumab","longName":"3187730","preferredDefinition":"Arm A = Paclitaxel +/- Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AEF897D-E46A-105D-E040-BB89AD4361BA","latestVersionIndicator":"Yes","beginDate":"2011-01-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84F3-3460-E053-4EBD850A1FCF","beginDate":"2011-01-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 6","valueDescription":"Arm 6","ValueMeaning":{"publicId":"3185117","version":"1","preferredName":"Arm 6","longName":"3185117","preferredDefinition":"Arm 6","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4DEAEF-2132-7F0A-E040-BB89AD4378B5","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-84FD-3460-E053-4EBD850A1FCF","beginDate":"2011-01-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 5","valueDescription":"Arm 5","ValueMeaning":{"publicId":"3185118","version":"1","preferredName":"Arm 5","longName":"3185118","preferredDefinition":"Arm 5","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4DEAEF-2155-7F0A-E040-BB89AD4378B5","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8507-3460-E053-4EBD850A1FCF","beginDate":"2011-01-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Raloxifene","valueDescription":"Raloxifene","ValueMeaning":{"publicId":"3190407","version":"1","preferredName":"Raloxifene","longName":"3190407","preferredDefinition":"A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to and interacts with estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects.  In postmenopausal women, raloxifene may reduce the risk of strokes, osteoporosis and breast cancer. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raloxifene","conceptCode":"C1518","definition":"A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BDF1709-A190-FC2F-E040-BB89AD4345C7","latestVersionIndicator":"Yes","beginDate":"2011-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8511-3460-E053-4EBD850A1FCF","beginDate":"2011-02-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"IV carboplatin","valueDescription":"Intravenous Carboplatin","ValueMeaning":{"publicId":"3188869","version":"1","preferredName":"Intravenous Carboplatin","longName":"3188869","preferredDefinition":"(in-tra-VEE-nus) IV. Within a blood vessel.: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous","conceptCode":"C13346","definition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B7A3828-EA57-316D-E040-BB89AD432EE5","latestVersionIndicator":"Yes","beginDate":"2011-02-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-851B-3460-E053-4EBD850A1FCF","beginDate":"2011-02-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"IP carboplatin","valueDescription":"Intraperitoneal Carboplatin","ValueMeaning":{"publicId":"3188870","version":"1","preferredName":"Intraperitoneal Carboplatin","longName":"3188870","preferredDefinition":"(IN-tra-per-ih-toe-NEE-al) IP.  Within the peritoneal cavity (the area that contains the abdominal organs).: A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraperitoneal","conceptCode":"C13352","definition":"Relating to the peritoneal cavity as the intended site of administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B7A3828-EA7D-316D-E040-BB89AD432EE5","latestVersionIndicator":"Yes","beginDate":"2011-02-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8525-3460-E053-4EBD850A1FCF","beginDate":"2011-02-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"IP cisplatin","valueDescription":"Intraperitoneal Cisplatin","ValueMeaning":{"publicId":"3188871","version":"1","preferredName":"Intraperitoneal Cisplatin","longName":"3188871","preferredDefinition":"(IN-tra-per-ih-toe-NEE-al) IP.  Within the peritoneal cavity (the area that contains the abdominal organs).: An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraperitoneal","conceptCode":"C13352","definition":"Relating to the peritoneal cavity as the intended site of administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B7A3828-EAA3-316D-E040-BB89AD432EE5","latestVersionIndicator":"Yes","beginDate":"2011-02-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-852F-3460-E053-4EBD850A1FCF","beginDate":"2011-02-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Regimen 2","valueDescription":"Regimen 2","ValueMeaning":{"publicId":"3249290","version":"1","preferredName":"Regimen 2","longName":"3249290","preferredDefinition":"Regimen 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-2354-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-06-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8539-3460-E053-4EBD850A1FCF","beginDate":"2011-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Regimen 1","valueDescription":"Regimen 1","ValueMeaning":{"publicId":"3249291","version":"1","preferredName":"Regimen 1","longName":"3249291","preferredDefinition":"Regimen 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-2377-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-06-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8543-3460-E053-4EBD850A1FCF","beginDate":"2011-06-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"RD","valueDescription":"Restoration with DBA","ValueMeaning":{"publicId":"3261261","version":"1","preferredName":"Restoration with DBA","longName":"3261261","preferredDefinition":"Restoration with DBA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6679-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-854D-3460-E053-4EBD850A1FCF","beginDate":"2011-08-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"RR","valueDescription":"Restoration with RMGI","ValueMeaning":{"publicId":"3261262","version":"1","preferredName":"Restoration with RMGI","longName":"3261262","preferredDefinition":"Restoration with RMGI","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-669C-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8557-3460-E053-4EBD850A1FCF","beginDate":"2011-08-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Dose Finding: Arm 1","valueDescription":"Dose Finding: Arm 1","ValueMeaning":{"publicId":"3794713","version":"1","preferredName":"Dose Finding: Arm 1","longName":"3794713","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A number with no fractional part, including the negative and positive numbers as well as zero.::1: The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Maximum Tolerated Dose","conceptCode":"C94489","definition":"The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E010110A-EAC7-64DE-E040-BB89AD431324","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8561-3460-E053-4EBD850A1FCF","beginDate":"2013-06-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B - CRd","valueDescription":"Arm B - CRd","ValueMeaning":{"publicId":"3812975","version":"1","preferredName":"Arm B - CRd","longName":"3812975","preferredDefinition":"Arm B - CRd","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1CAEFC2-C669-47F9-E040-BB89AD436FDA","latestVersionIndicator":"Yes","beginDate":"2013-07-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-07-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-856B-3460-E053-4EBD850A1FCF","beginDate":"2013-07-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A - VRd","valueDescription":"Arm A - VRd","ValueMeaning":{"publicId":"3812976","version":"1","preferredName":"Arm A - VRd","longName":"3812976","preferredDefinition":"Arm A - VRd","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1CAEFC2-C68C-47F9-E040-BB89AD436FDA","latestVersionIndicator":"Yes","beginDate":"2013-07-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-07-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8575-3460-E053-4EBD850A1FCF","beginDate":"2013-07-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Gemcitabine + Erlotinib","valueDescription":"Gemcitabine + Erlotinib","ValueMeaning":{"publicId":"3775511","version":"1","preferredName":"Gemcitabine + Erlotinib","longName":"3775511","preferredDefinition":"Gemacitabine + Erlotinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE7C4E7B-BB0F-167C-E040-BB89AD432E95","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-857F-3460-E053-4EBD850A1FCF","beginDate":"2013-06-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"3145831","version":"1","preferredName":"Gemcitabine","longName":"3145831","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A1DB-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8589-3460-E053-4EBD850A1FCF","beginDate":"2013-06-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Dose Finding: Arm 2","valueDescription":"Dose Finding: Arm 2","ValueMeaning":{"publicId":"3794708","version":"1","preferredName":"Dose Finding: Arm 2","longName":"3794708","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A number with no fractional part, including the negative and positive numbers as well as zero.::2: The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Maximum Tolerated Dose","conceptCode":"C94489","definition":"The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0105293-0D64-90F8-E040-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8593-3460-E053-4EBD850A1FCF","beginDate":"2013-06-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Intratumoral Drug Distribution Stage 2","valueDescription":"Intratumoral Drug Distribution Stage 2","ValueMeaning":{"publicId":"3794709","version":"1","preferredName":"Intratumoral Drug Distribution Stage 2","longName":"3794709","preferredDefinition":"Any distinct time period in a sequence of events.: A number with no fractional part, including the negative and positive numbers as well as zero.::2: Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.: The act of distributing or spreading or apportioning.: Direct administration of a therapeutic agent into a malignant tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage","conceptCode":"C48308","definition":"Any distinct time period in a sequence of events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Distribution","conceptCode":"C45273","definition":"The act of distributing or spreading or apportioning.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intratumoral Therapy","conceptCode":"C62722","definition":"Direct administration of a therapeutic agent into a malignant tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0105293-0D8F-90F8-E040-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-859D-3460-E053-4EBD850A1FCF","beginDate":"2013-06-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Intratumoral Drug Distribution Stage 1","valueDescription":"Intratumoral Drug Distribution Stage 1","ValueMeaning":{"publicId":"3794710","version":"1","preferredName":"Intratumoral Drug Distribution Stage 1","longName":"3794710","preferredDefinition":"Any distinct time period in a sequence of events.: A number with no fractional part, including the negative and positive numbers as well as zero.::1: Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.: The act of distributing or spreading or apportioning.: Direct administration of a therapeutic agent into a malignant tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage","conceptCode":"C48308","definition":"Any distinct time period in a sequence of events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Distribution","conceptCode":"C45273","definition":"The act of distributing or spreading or apportioning.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intratumoral Therapy","conceptCode":"C62722","definition":"Direct administration of a therapeutic agent into a malignant tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0105293-0DB8-90F8-E040-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85A7-3460-E053-4EBD850A1FCF","beginDate":"2013-06-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Combination Dose Cohort","valueDescription":"Combination Dose Cohort","ValueMeaning":{"publicId":"3794712","version":"1","preferredName":"Combination Dose Cohort","longName":"3794712","preferredDefinition":"Drug therapy with two or more drugs given separately or together for a combined effect.: A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time. : A group of individuals, identified by a common characteristic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combination Drug Therapy","conceptCode":"C16144","definition":"Drug therapy with two or more drugs given separately or together for a combined effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0105293-0DDF-90F8-E040-BB89AD43140D","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85B1-3460-E053-4EBD850A1FCF","beginDate":"2013-06-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Reference Group","valueDescription":"Reference Group","ValueMeaning":{"publicId":"4276811","version":"1","preferredName":"Reference Group","longName":"4276811","preferredDefinition":"Reference Group","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7953FB8-5033-4D7E-E040-BB89AD4327BF","latestVersionIndicator":"Yes","beginDate":"2014-04-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85BB-3460-E053-4EBD850A1FCF","beginDate":"2014-04-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group A","valueDescription":"Group A","ValueMeaning":{"publicId":"2979155","version":"1","preferredName":"Group A","longName":"2979155","preferredDefinition":"Group A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C7FBC29-D96C-FF67-E040-BB89AD4353BF","latestVersionIndicator":"Yes","beginDate":"2010-01-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85C5-3460-E053-4EBD850A1FCF","beginDate":"2014-04-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part 2 - Group B","valueDescription":"Part 2 - Group B","ValueMeaning":{"publicId":"4162671","version":"1","preferredName":"Part 2 - Group B","longName":"4162671","preferredDefinition":"Part 2 - Group B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B2F954-7307-5295-E040-BB89AD4318B5","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85CF-3460-E053-4EBD850A1FCF","beginDate":"2014-02-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part 2 - Group A","valueDescription":"Part 2 - Group A","ValueMeaning":{"publicId":"4162672","version":"1","preferredName":"Part 2 - Group A","longName":"4162672","preferredDefinition":"Part 2 - Group A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B2F954-732A-5295-E040-BB89AD4318B5","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85D9-3460-E053-4EBD850A1FCF","beginDate":"2014-02-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part 1 - Cohort B","valueDescription":"Part 1 - Cohort B","ValueMeaning":{"publicId":"4162673","version":"1","preferredName":"Part 1 - Cohort B","longName":"4162673","preferredDefinition":"Part 1 - Cohort B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B2F954-734D-5295-E040-BB89AD4318B5","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85E3-3460-E053-4EBD850A1FCF","beginDate":"2014-02-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part 1 - Cohort A","valueDescription":"Part 1 - Cohort A","ValueMeaning":{"publicId":"4162674","version":"1","preferredName":"Part 1 - Cohort A","longName":"4162674","preferredDefinition":"Part 1 - Cohort A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B2F954-7370-5295-E040-BB89AD4318B5","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-18","modifiedBy":"CHENR","dateModified":"2019-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85ED-3460-E053-4EBD850A1FCF","beginDate":"2014-02-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B: Intervention","valueDescription":"Arm B: Intervention","ValueMeaning":{"publicId":"4492291","version":"1","preferredName":"Arm B: Intervention","longName":"4492291","preferredDefinition":"Arm B: Intervention","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03BFD6FD-0DC8-8A7A-E050-BB89AD43654E","latestVersionIndicator":"Yes","beginDate":"2014-09-23","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-85F7-3460-E053-4EBD850A1FCF","beginDate":"2014-09-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A: Non-Intervention","valueDescription":"Arm A: Non-Intervention","ValueMeaning":{"publicId":"4492292","version":"1","preferredName":"Arm A: Non-Intervention","longName":"4492292","preferredDefinition":"Arm A: Non-Intervention","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03BFD6FD-0DEB-8A7A-E050-BB89AD43654E","latestVersionIndicator":"Yes","beginDate":"2014-09-23","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8601-3460-E053-4EBD850A1FCF","beginDate":"2014-09-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part 3","valueDescription":"Part 3","ValueMeaning":{"publicId":"4701447","version":"1","preferredName":"Part 3","longName":"4701447","preferredDefinition":"Part 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E37751E-7008-9613-E050-BB89AD432893","latestVersionIndicator":"Yes","beginDate":"2015-02-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-03","modifiedBy":"TSESU","dateModified":"2019-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-860B-3460-E053-4EBD850A1FCF","beginDate":"2015-02-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part 2","valueDescription":"Part 2","ValueMeaning":{"publicId":"4274853","version":"1","preferredName":"Part 2","longName":"4274853","preferredDefinition":"Part 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F745FF5D-0C24-F26D-E040-BB89AD432872","latestVersionIndicator":"Yes","beginDate":"2014-04-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-04-17","modifiedBy":"TSESU","dateModified":"2019-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8615-3460-E053-4EBD850A1FCF","beginDate":"2015-02-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part 1","valueDescription":"Part 1","ValueMeaning":{"publicId":"4274855","version":"1","preferredName":"Part 1","longName":"4274855","preferredDefinition":"Part 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F745FF5D-0C6A-F26D-E040-BB89AD432872","latestVersionIndicator":"Yes","beginDate":"2014-04-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-04-17","modifiedBy":"TSESU","dateModified":"2019-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-861F-3460-E053-4EBD850A1FCF","beginDate":"2015-02-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"NF2","valueDescription":"NF2","ValueMeaning":{"publicId":"4898951","version":"1","preferredName":"NF2","longName":"4898951","preferredDefinition":"NF2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AD9C5A4-73F1-98DF-E050-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2015-07-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8629-3460-E053-4EBD850A1FCF","beginDate":"2015-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SMO","valueDescription":"SMO","ValueMeaning":{"publicId":"4898952","version":"1","preferredName":"SMO","longName":"4898952","preferredDefinition":"SMO","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AD9C5A4-7414-98DF-E050-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2015-07-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8633-3460-E053-4EBD850A1FCF","beginDate":"2015-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"AKT1","valueDescription":"AKT1","ValueMeaning":{"publicId":"4898953","version":"1","preferredName":"AKT1","longName":"4898953","preferredDefinition":"AKT1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AD9C5A4-7437-98DF-E050-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2015-07-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-863D-3460-E053-4EBD850A1FCF","beginDate":"2015-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group B","valueDescription":"Group B","ValueMeaning":{"publicId":"2979154","version":"1","preferredName":"Group B","longName":"2979154","preferredDefinition":"Group B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C7FBC29-D949-FF67-E040-BB89AD4353BF","latestVersionIndicator":"Yes","beginDate":"2010-01-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8647-3460-E053-4EBD850A1FCF","beginDate":"2015-12-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part B: Anti-CD137 + Anti-PD1","valueDescription":"Part B: Anti-CD137 + Anti-PD1","ValueMeaning":{"publicId":"5119192","version":"1","preferredName":"Part B: Anti-CD137 + Anti-PD1","longName":"5119192","preferredDefinition":"Part B: Anti-CD137 + Anti-PD1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B47257B-9689-43D5-E050-BB89AD43181A","latestVersionIndicator":"Yes","beginDate":"2016-02-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-02-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8651-3460-E053-4EBD850A1FCF","beginDate":"2016-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part B: Anti-LAG-3 + Anti-PD1","valueDescription":"Part B: Anti-LAG-3 + Anti-PD1","ValueMeaning":{"publicId":"5119193","version":"1","preferredName":"Part B: Anti-LAG-3 + Anti-PD1","longName":"5119193","preferredDefinition":"Part B: Anti-LAG-3 + Anti-PD1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B47257B-96AC-43D5-E050-BB89AD43181A","latestVersionIndicator":"Yes","beginDate":"2016-02-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-02-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-865B-3460-E053-4EBD850A1FCF","beginDate":"2016-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part A: Anti-CD137 Monotherapy","valueDescription":"Part A: Anti-CD137 Monotherapy","ValueMeaning":{"publicId":"5119194","version":"1","preferredName":"Part A: Anti-CD137 Monotherapy","longName":"5119194","preferredDefinition":"Part A: Anti-CD137 Monotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B47257B-96CF-43D5-E050-BB89AD43181A","latestVersionIndicator":"Yes","beginDate":"2016-02-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-02-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8665-3460-E053-4EBD850A1FCF","beginDate":"2016-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part A: Anti-LAG-3 Monotherapy","valueDescription":"Part A: Anti-LAG-3 Monotherapy","ValueMeaning":{"publicId":"5119195","version":"1","preferredName":"Part A: Anti-LAG-3 Monotherapy","longName":"5119195","preferredDefinition":"Part A: Anti-LAG-3 Monotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B47257B-96F2-43D5-E050-BB89AD43181A","latestVersionIndicator":"Yes","beginDate":"2016-02-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-02-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-866F-3460-E053-4EBD850A1FCF","beginDate":"2016-02-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part B","valueDescription":"Part B","ValueMeaning":{"publicId":"3151335","version":"1","preferredName":"Part B","longName":"3151335","preferredDefinition":"Part B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9299B94C-3FCB-BA08-E040-BB89AD430CAF","latestVersionIndicator":"Yes","beginDate":"2010-10-14","endDate":null,"createdBy":"LUY","dateCreated":"2010-10-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8679-3460-E053-4EBD850A1FCF","beginDate":"2016-02-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part A","valueDescription":"Part A","ValueMeaning":{"publicId":"3151336","version":"1","preferredName":"Part A","longName":"3151336","preferredDefinition":"Part A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9299B94C-3FEE-BA08-E040-BB89AD430CAF","latestVersionIndicator":"Yes","beginDate":"2010-10-14","endDate":null,"createdBy":"LUY","dateCreated":"2010-10-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8683-3460-E053-4EBD850A1FCF","beginDate":"2016-02-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B: Carboplatin + Paclitaxel","valueDescription":"Arm B: Carboplatin + Paclitaxel","ValueMeaning":{"publicId":"5041680","version":"1","preferredName":"Arm B: Carboplatin + Paclitaxel","longName":"5041680","preferredDefinition":"Arm B: Carboplatin + Paclitaxel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23574F9B-85D9-10FE-E050-BB89AD434AF1","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-868D-3460-E053-4EBD850A1FCF","beginDate":"2015-10-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A: Cisplatin + 5-FU","valueDescription":"Arm A: Cisplatin + 5-FU","ValueMeaning":{"publicId":"5041681","version":"1","preferredName":"Arm A: Cisplatin + 5-FU","longName":"5041681","preferredDefinition":"Arm A: Cisplatin + 5-FU","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23574F9B-85FC-10FE-E050-BB89AD434AF1","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8697-3460-E053-4EBD850A1FCF","beginDate":"2015-10-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 4:  Usual care","valueDescription":"Arm 4:  Usual care","ValueMeaning":{"publicId":"5750381","version":"1","preferredName":"Arm 4:  Usual care","longName":"5750381","preferredDefinition":"Arm 4:  Usual care","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CE71D1A-6CA6-3E81-E053-F662850ADF0F","latestVersionIndicator":"Yes","beginDate":"2017-04-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86A1-3460-E053-4EBD850A1FCF","beginDate":"2017-04-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 3:  During-consultation Decision Aid Only","valueDescription":"Arm 3:  During-consultation Decision Aid Only","ValueMeaning":{"publicId":"5750382","version":"1","preferredName":"Arm 3:  During-consultation Decision Aid Only","longName":"5750382","preferredDefinition":"Arm 3:  During-consultation Decision Aid Only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CE71D1A-6CC9-3E81-E053-F662850ADF0F","latestVersionIndicator":"Yes","beginDate":"2017-04-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86AB-3460-E053-4EBD850A1FCF","beginDate":"2017-04-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2:  Pre-consultation Decision Aid Only","valueDescription":"Arm 2:  Pre-consultation Decision Aid Only","ValueMeaning":{"publicId":"5750383","version":"1","preferredName":"Arm 2:  Pre-consultation Decision Aid Only","longName":"5750383","preferredDefinition":"Arm 2:  Pre-consultation Decision Aid Only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CE71D1A-6CEC-3E81-E053-F662850ADF0F","latestVersionIndicator":"Yes","beginDate":"2017-04-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86B5-3460-E053-4EBD850A1FCF","beginDate":"2017-04-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1:  Pre- and During-consultation Decision Aids","valueDescription":"Arm 1:  Pre- and During-consultation Decision Aids","ValueMeaning":{"publicId":"5750384","version":"1","preferredName":"Arm 1:  Pre- and During-consultation Decision Aids","longName":"5750384","preferredDefinition":"Arm 1:  Pre- and During-consultation Decision Aids","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CE71D1A-6D0F-3E81-E053-F662850ADF0F","latestVersionIndicator":"Yes","beginDate":"2017-04-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86BF-3460-E053-4EBD850A1FCF","beginDate":"2017-04-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Cohort B","valueDescription":"Cohort B","ValueMeaning":{"publicId":"5859538","version":"1","preferredName":"Cohort B","longName":"5859538","preferredDefinition":"Cohort B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"51742E37-9C76-45E2-E053-F662850AA03A","latestVersionIndicator":"Yes","beginDate":"2017-06-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86C9-3460-E053-4EBD850A1FCF","beginDate":"2017-06-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Cohort A","valueDescription":"Cohort","ValueMeaning":{"publicId":"5859539","version":"1","preferredName":"Cohort","longName":"5859539","preferredDefinition":"A group of individuals, identified by a common characteristic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"51742E37-9C99-45E2-E053-F662850AA03A","latestVersionIndicator":"Yes","beginDate":"2017-06-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86D3-3460-E053-4EBD850A1FCF","beginDate":"2017-06-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Cohort B- Prior RT and progressive disease","valueDescription":"Cohort Prior Radiation Therapy And Progressive Disease","ValueMeaning":{"publicId":"5859534","version":"1","preferredName":"Cohort Prior Radiation Therapy And Progressive Disease","longName":"5859534","preferredDefinition":"A group of individuals, identified by a common characteristic.: Definition not available.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A disease process that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Prior Radiation Therapy","conceptCode":"C15477","definition":"An indicator that a person previously received radiation treatment for the same condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"516A0BFB-40EE-5F0A-E053-F662850AD196","latestVersionIndicator":"Yes","beginDate":"2017-06-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86DD-3460-E053-4EBD850A1FCF","beginDate":"2017-06-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Cohort A- No prior therapy","valueDescription":"Cohort No Prior Therapy","ValueMeaning":{"publicId":"5859535","version":"1","preferredName":"Cohort No Prior Therapy","longName":"5859535","preferredDefinition":"A group of individuals, identified by a common characteristic.: No prior treatment for the study disorder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"No Prior Therapy","conceptCode":"C118903","definition":"No prior treatment for the study disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"516A0BFB-4114-5F0A-E053-F662850AD196","latestVersionIndicator":"Yes","beginDate":"2017-06-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86E7-3460-E053-4EBD850A1FCF","beginDate":"2017-06-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"E - INO-8000 + INO-9012 (3 mg)","valueDescription":"E - INO-8000 + INO-9012 (3 mg)","ValueMeaning":{"publicId":"6184032","version":"1","preferredName":"E - INO-8000 + INO-9012 (3 mg)","longName":"6184032","preferredDefinition":"E - INO-8000 + INO-9012 (3 mg)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69BB1A7A-4F74-42BC-E053-F662850A9E22","latestVersionIndicator":"Yes","beginDate":"2018-04-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2018-04-13","modifiedBy":"ONEDATA","dateModified":"2018-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86F1-3460-E053-4EBD850A1FCF","beginDate":"2018-04-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"D - INO-8000 + INO-9012 (1 mg)","valueDescription":"D - INO-8000 + INO-9012 (1 mg)","ValueMeaning":{"publicId":"6184033","version":"1","preferredName":"D - INO-8000 + INO-9012 (1 mg)","longName":"6184033","preferredDefinition":"D - INO-8000 + INO-9012 (1 mg)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69BB1A7A-4F97-42BC-E053-F662850A9E22","latestVersionIndicator":"Yes","beginDate":"2018-04-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2018-04-13","modifiedBy":"ONEDATA","dateModified":"2018-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-86FB-3460-E053-4EBD850A1FCF","beginDate":"2018-04-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"C - INO-8000 + INO-9012 (0.3mg)","valueDescription":"C - INO-8000 + INO-9012 (0.3mg)","ValueMeaning":{"publicId":"6184034","version":"1","preferredName":"C - INO-8000 + INO-9012 (0.3mg)","longName":"6184034","preferredDefinition":"C - INO-8000 + INO-9012 (0.3mg)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69BB1A7A-4FBA-42BC-E053-F662850A9E22","latestVersionIndicator":"Yes","beginDate":"2018-04-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2018-04-13","modifiedBy":"ONEDATA","dateModified":"2018-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8705-3460-E053-4EBD850A1FCF","beginDate":"2018-04-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"B - INO-8000","valueDescription":"B - INO-8000","ValueMeaning":{"publicId":"6184035","version":"1","preferredName":"B - INO-8000","longName":"6184035","preferredDefinition":"B - INO-8000","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69BB1A7A-4FDD-42BC-E053-F662850A9E22","latestVersionIndicator":"Yes","beginDate":"2018-04-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2018-04-13","modifiedBy":"ONEDATA","dateModified":"2018-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-870F-3460-E053-4EBD850A1FCF","beginDate":"2018-04-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 4: Anti-CD137 + Anti-PD1","valueDescription":"Group 4: Anti-CD137 + Anti-PD1","ValueMeaning":{"publicId":"6270485","version":"1","preferredName":"Group 4: Anti-CD137 + Anti-PD1","longName":"6270485","preferredDefinition":"Group 4: Anti-CD137 + Anti-PD1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BA3BA84-9FD5-7C2E-E053-F662850A9A2C","latestVersionIndicator":"Yes","beginDate":"2018-05-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-05-07","modifiedBy":"ONEDATA","dateModified":"2018-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8719-3460-E053-4EBD850A1FCF","beginDate":"2018-05-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 3: Anti-LAG-3 + Anti-PD1","valueDescription":"Group 3: Anti-LAG-3 + Anti-PD1","ValueMeaning":{"publicId":"6270486","version":"1","preferredName":"Group 3: Anti-LAG-3 + Anti-PD1","longName":"6270486","preferredDefinition":"Group 3: Anti-LAG-3 + Anti-PD1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BA3BA84-9FF8-7C2E-E053-F662850A9A2C","latestVersionIndicator":"Yes","beginDate":"2018-05-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-05-07","modifiedBy":"ONEDATA","dateModified":"2018-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8723-3460-E053-4EBD850A1FCF","beginDate":"2018-05-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 2: Anti-CD137 Monotherapy","valueDescription":"Group 2: Anti-CD137 Monotherapy","ValueMeaning":{"publicId":"6270487","version":"1","preferredName":"Group 2: Anti-CD137 Monotherapy","longName":"6270487","preferredDefinition":"Group 2: Anti-CD137 Monotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BA3BA84-A01B-7C2E-E053-F662850A9A2C","latestVersionIndicator":"Yes","beginDate":"2018-05-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-05-07","modifiedBy":"ONEDATA","dateModified":"2018-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-872D-3460-E053-4EBD850A1FCF","beginDate":"2018-05-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 1: Anti-LAG-3 Monotherapy","valueDescription":"Group 1: Anti-LAG-3 Monotherapy","ValueMeaning":{"publicId":"6270488","version":"1","preferredName":"Group 1: Anti-LAG-3 Monotherapy","longName":"6270488","preferredDefinition":"Group 1: Anti-LAG-3 Monotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BA3BA84-A03E-7C2E-E053-F662850A9A2C","latestVersionIndicator":"Yes","beginDate":"2018-05-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-05-07","modifiedBy":"ONEDATA","dateModified":"2018-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8737-3460-E053-4EBD850A1FCF","beginDate":"2018-05-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Clinic is in Decision Aid Intervention","valueDescription":"Clinic Decision Assistance Interventions","ValueMeaning":{"publicId":"6423335","version":"1","preferredName":"Clinic Decision Assistance Interventions","longName":"6423335","preferredDefinition":"A health care facility where patients are admitted to get treatment provided by a group of physicians practicing medicine together.: A position, opinion, or judgment reached on an issue under consideration.: The act of contributing to the fulfillment of a need or furtherance of an effort.: An action or ministration that produces an effect or that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinic","conceptCode":"C51282","definition":"A health care facility where patients are admitted to get treatment provided by a group of physicians practicing medicine together.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Decision","conceptCode":"C53285","definition":"A position, opinion, or judgment reached on an issue under consideration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Assistance","conceptCode":"C89271","definition":"The act of contributing to the fulfillment of a need or furtherance of an effort.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Interventions","conceptCode":"C16197","definition":"An action or ministration that produces an effect or that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"750C4345-08AA-2BF3-E053-F662850A2FFA","latestVersionIndicator":"Yes","beginDate":"2018-09-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-09-04","modifiedBy":"ONEDATA","dateModified":"2018-09-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8741-3460-E053-4EBD850A1FCF","beginDate":"2018-09-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Clinic is in Usual Care","valueDescription":"Clinic Usual Care","ValueMeaning":{"publicId":"6423336","version":"1","preferredName":"Clinic Usual Care","longName":"6423336","preferredDefinition":"A health care facility where patients are admitted to get treatment provided by a group of physicians practicing medicine together.: That which is considered customary.: The work of attending to someone or something.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinic","conceptCode":"C51282","definition":"A health care facility where patients are admitted to get treatment provided by a group of physicians practicing medicine together.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Usual","conceptCode":"C102843","definition":"That which is considered customary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Care","conceptCode":"C61488","definition":"The work of attending to someone or something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"750C4345-08D1-2BF3-E053-F662850A2FFA","latestVersionIndicator":"Yes","beginDate":"2018-09-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-09-04","modifiedBy":"ONEDATA","dateModified":"2018-09-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-874B-3460-E053-4EBD850A1FCF","beginDate":"2018-09-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Cohort C","valueDescription":"Cohort C","ValueMeaning":{"publicId":"2580619","version":"1","preferredName":"Cohort C","longName":"2580619","preferredDefinition":"Cohort C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-07F8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-24","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-08-24","modifiedBy":"MAESKEB","dateModified":"2006-08-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8755-3460-E053-4EBD850A1FCF","beginDate":"2018-09-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Randomization","valueDescription":"Randomization","ValueMeaning":{"publicId":"2659950","version":"1","preferredName":"Randomization","longName":"2659950","preferredDefinition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Randomization","conceptCode":"C25196","definition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"33BEA2A0-D6EE-6CE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-25","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-25","modifiedBy":"ONEDATA","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-875F-3460-E053-4EBD850A1FCF","beginDate":"2018-09-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Standard of Care, with decision Aid","valueDescription":"Best Practice With Decision Assistance","ValueMeaning":{"publicId":"6547850","version":"1","preferredName":"Best Practice With Decision Assistance","longName":"6547850","preferredDefinition":"In medicine, treatment that experts agree is appropriate, accepted, and widely used. Health care providers are obligated to provide patients with the standard of care.: Used to indicate the presence of something or someone.: A position, opinion, or judgment reached on an issue under consideration.: The act of contributing to the fulfillment of a need or furtherance of an effort.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best Practice","conceptCode":"C94396","definition":"An informed treatment recommendation that is expected to be helpful to the greatest number of people within a certain patient group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Decision","conceptCode":"C53285","definition":"A position, opinion, or judgment reached on an issue under consideration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assistance","conceptCode":"C89271","definition":"The act of contributing to the fulfillment of a need or furtherance of an effort.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"79EF2811-540A-38C6-E053-F662850AFF0F","latestVersionIndicator":"Yes","beginDate":"2018-11-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-11-05","modifiedBy":"ONEDATA","dateModified":"2018-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8769-3460-E053-4EBD850A1FCF","beginDate":"2018-11-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Standard of Care, No decision Aid","valueDescription":"Best Practice No Decision Assistance","ValueMeaning":{"publicId":"6547851","version":"1","preferredName":"Best Practice No Decision Assistance","longName":"6547851","preferredDefinition":"In medicine, treatment that experts agree is appropriate, accepted, and widely used. Health care providers are obligated to provide patients with the standard of care.: The non-affirmative response to a question.: A position, opinion, or judgment reached on an issue under consideration.: The act of contributing to the fulfillment of a need or furtherance of an effort.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best Practice","conceptCode":"C94396","definition":"An informed treatment recommendation that is expected to be helpful to the greatest number of people within a certain patient group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Decision","conceptCode":"C53285","definition":"A position, opinion, or judgment reached on an issue under consideration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assistance","conceptCode":"C89271","definition":"The act of contributing to the fulfillment of a need or furtherance of an effort.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"79EF2811-5432-38C6-E053-F662850AFF0F","latestVersionIndicator":"Yes","beginDate":"2018-11-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-11-05","modifiedBy":"ONEDATA","dateModified":"2018-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8773-3460-E053-4EBD850A1FCF","beginDate":"2018-11-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Safety Cohort","valueDescription":"Safety Study Cohort","ValueMeaning":{"publicId":"6535661","version":"1","preferredName":"Safety Study Cohort","longName":"6535661","preferredDefinition":"A study of the relative safety of treatment of a disease. Usually this is a Phase I or II trial.: A group of individuals, identified by a common characteristic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Safety Study","conceptCode":"C49667","definition":"A study of the relative safety of treatment of a disease. Usually this is a Phase I or II trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78D42D16-6EF9-1E45-E053-F662850A537F","latestVersionIndicator":"Yes","beginDate":"2018-10-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-22","modifiedBy":"ONEDATA","dateModified":"2018-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-877D-3460-E053-4EBD850A1FCF","beginDate":"2018-10-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Treatment Group 1","valueDescription":"Sezary Syndrome Mycosis Fungoides","ValueMeaning":{"publicId":"6546041","version":"1","preferredName":"Sezary Syndrome Mycosis Fungoides","longName":"6546041","preferredDefinition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001): A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"79885B2D-D526-3A91-E053-F662850A7B65","latestVersionIndicator":"Yes","beginDate":"2018-10-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-10-31","modifiedBy":"MAESKEB","dateModified":"2018-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8787-3460-E053-4EBD850A1FCF","beginDate":"2018-10-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Treatment Group 2","valueDescription":"Synovial Sarcoma","ValueMeaning":{"publicId":"3251907","version":"1","preferredName":"Synovial Sarcoma","longName":"3251907","preferredDefinition":"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Synovial Sarcoma","conceptCode":"C3400","definition":"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A77CE4DC-22FC-EFB7-E040-BB89AD430FFC","latestVersionIndicator":"Yes","beginDate":"2011-07-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-07","modifiedBy":"MAESKEB","dateModified":"2018-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8791-3460-E053-4EBD850A1FCF","beginDate":"2018-10-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Initially randomized to Arm 2 and a response of BM MRD- CR","valueDescription":"Initial Randomized To Protocol Treatment Arm Two And Disease Response Bone Marrow Minimal Residual Disease Complete Remission","ValueMeaning":{"publicId":"6438393","version":"1","preferredName":"Initial Randomized To Protocol Treatment Arm Two And Disease Response Bone Marrow Minimal Residual Disease Complete Remission","longName":"6438393","preferredDefinition":"occurring at the beginning.: Describes an experiment or clinical trial in which animal or human subjects are assigned by chance to separate groups that compare different treatments.: Used as a function word to indicate direction, purpose, or movement.: A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.: The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Initial","conceptCode":"CL052284","definition":"occurring at the beginning.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"9"},{"longName":"Randomized","conceptCode":"C28295","definition":"Describes an experiment or clinical trial in which animal or human subjects are assigned by chance to separate groups that compare different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Two","conceptCode":"C66833","definition":"A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76C663AB-9F7F-4FFF-E053-F662850AD110","latestVersionIndicator":"Yes","beginDate":"2018-09-26","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-09-26","modifiedBy":"ONEDATA","dateModified":"2018-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-879B-3460-E053-4EBD850A1FCF","beginDate":"2018-09-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Initially randomized to Arm 2 and any response except BM MRD- CR","valueDescription":"Initial Randomized To Protocol Treatment Arm Two And Any Disease Response Other Than Bone Marrow Minimal Residual Disease Complete Remission","ValueMeaning":{"publicId":"6438394","version":"1","preferredName":"Initial Randomized To Protocol Treatment Arm Two And Any Disease Response Other Than Bone Marrow Minimal Residual Disease Complete Remission","longName":"6438394","preferredDefinition":"occurring at the beginning.: Describes an experiment or clinical trial in which animal or human subjects are assigned by chance to separate groups that compare different treatments.: Used as a function word to indicate direction, purpose, or movement.: A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: One, some, every, or all without specification.: The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.: Distinct from those already mentioned, listed, or considered.: The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Initial","conceptCode":"CL052284","definition":"occurring at the beginning.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"11"},{"longName":"Randomized","conceptCode":"C28295","definition":"Describes an experiment or clinical trial in which animal or human subjects are assigned by chance to separate groups that compare different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Two","conceptCode":"C66833","definition":"A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Any","conceptCode":"C81168","definition":"One, some, every, or all without specification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Other Than","conceptCode":"C151896","definition":"Distinct from those already mentioned, listed, or considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76C663AB-9FAF-4FFF-E053-F662850AD110","latestVersionIndicator":"Yes","beginDate":"2018-09-26","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-09-26","modifiedBy":"ONEDATA","dateModified":"2018-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87A5-3460-E053-4EBD850A1FCF","beginDate":"2018-09-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Intially randomized to Arm 1","valueDescription":"Initial Randomized To Protocol Treatment Arm One","ValueMeaning":{"publicId":"6438395","version":"1","preferredName":"Initial Randomized To Protocol Treatment Arm One","longName":"6438395","preferredDefinition":"occurring at the beginning.: Describes an experiment or clinical trial in which animal or human subjects are assigned by chance to separate groups that compare different treatments.: Used as a function word to indicate direction, purpose, or movement.: A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: The smallest natural number and quantity it denotes: a single entity, unit, or object.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Initial","conceptCode":"CL052284","definition":"occurring at the beginning.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"4"},{"longName":"Randomized","conceptCode":"C28295","definition":"Describes an experiment or clinical trial in which animal or human subjects are assigned by chance to separate groups that compare different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"One","conceptCode":"C66832","definition":"The smallest natural number and quantity it denotes: a single entity, unit, or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76C663AB-9FD8-4FFF-E053-F662850AD110","latestVersionIndicator":"Yes","beginDate":"2018-09-26","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-09-26","modifiedBy":"ONEDATA","dateModified":"2018-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87AF-3460-E053-4EBD850A1FCF","beginDate":"2018-09-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2: OPTI-Surg without coach","valueDescription":"Protocol Treatment Arm Two OPTI-Surg Toolkit Without Coach","ValueMeaning":{"publicId":"6631747","version":"1","preferredName":"Protocol Treatment Arm Two OPTI-Surg Toolkit Without Coach","longName":"6631747","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.: A set of pre-surgical questionnaires, including a frailty assessment, designed to provide resource-customized recommendations to address identified vulnerabilities in individual patients.: Used to indicate the absence or lack of something or someone.: Someone who teaches a special skill (e.g., how to implement a treatment or intervention).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Two","conceptCode":"C66833","definition":"A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"OPTI-Surg Toolkit","conceptCode":"C157482","definition":"A set of pre-surgical questionnaires, including a frailty assessment, designed to provide resource-customized recommendations to address identified vulnerabilities in individual patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Coach","conceptCode":"C157483","definition":"Someone who teaches a special skill (e.g., how to implement a treatment or intervention).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8137EC54-4EA4-4507-E053-F662850A2022","latestVersionIndicator":"Yes","beginDate":"2019-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-06","modifiedBy":"ONEDATA","dateModified":"2019-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87B9-3460-E053-4EBD850A1FCF","beginDate":"2019-02-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 3: OPTI-Surg with coach","valueDescription":"Protocol Treatment Arm Three OPTI-Surg Toolkit With Coach","ValueMeaning":{"publicId":"6631748","version":"1","preferredName":"Protocol Treatment Arm Three OPTI-Surg Toolkit With Coach","longName":"6631748","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.: A set of pre-surgical questionnaires, including a frailty assessment, designed to provide resource-customized recommendations to address identified vulnerabilities in individual patients.: Used to indicate the presence of something or someone.: Someone who teaches a special skill (e.g., how to implement a treatment or intervention).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Three","conceptCode":"C66834","definition":"A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"OPTI-Surg Toolkit","conceptCode":"C157482","definition":"A set of pre-surgical questionnaires, including a frailty assessment, designed to provide resource-customized recommendations to address identified vulnerabilities in individual patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Coach","conceptCode":"C157483","definition":"Someone who teaches a special skill (e.g., how to implement a treatment or intervention).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8137EC54-4ECD-4507-E053-F662850A2022","latestVersionIndicator":"Yes","beginDate":"2019-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-06","modifiedBy":"ONEDATA","dateModified":"2019-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87C3-3460-E053-4EBD850A1FCF","beginDate":"2019-02-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1: Usual Care","valueDescription":"Protocol Treatment Arm One Usual Care","ValueMeaning":{"publicId":"6625188","version":"1","preferredName":"Protocol Treatment Arm One Usual Care","longName":"6625188","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: The smallest natural number and quantity it denotes: a single entity, unit, or object.: That which is considered customary.: The work of attending to someone or something.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"One","conceptCode":"C66832","definition":"The smallest natural number and quantity it denotes: a single entity, unit, or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Usual","conceptCode":"C102843","definition":"That which is considered customary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Care","conceptCode":"C61488","definition":"The work of attending to someone or something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"80C7CA64-8609-2E07-E053-F662850A12D3","latestVersionIndicator":"Yes","beginDate":"2019-01-31","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-31","modifiedBy":"ONEDATA","dateModified":"2019-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87CD-3460-E053-4EBD850A1FCF","beginDate":"2019-01-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Surgical Portion","valueDescription":"Surgical Portion","ValueMeaning":{"publicId":"6688155","version":"1","preferredName":"Surgical Portion","longName":"6688155","preferredDefinition":"Surgical Portion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860BB033-02DF-2F3E-E053-F662850AF637","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87D7-3460-E053-4EBD850A1FCF","beginDate":"2019-04-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"GBM Arm","valueDescription":"GBM Arm","ValueMeaning":{"publicId":"6688156","version":"1","preferredName":"GBM Arm","longName":"6688156","preferredDefinition":"GBM Arm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860BB033-0302-2F3E-E053-F662850AF637","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87E1-3460-E053-4EBD850A1FCF","beginDate":"2019-04-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Phase I","valueDescription":"Phase I","ValueMeaning":{"publicId":"6686733","version":"1","preferredName":"Phase I","longName":"6686733","preferredDefinition":"Phase I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A6946B-F0EF-57FC-E053-F662850A0908","latestVersionIndicator":"Yes","beginDate":"2019-04-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-04","modifiedBy":"ONEDATA","dateModified":"2019-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87EB-3460-E053-4EBD850A1FCF","beginDate":"2019-04-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain - Abemaciclib (Arm 5)","valueDescription":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain - Abemaciclib (Arm 5)","ValueMeaning":{"publicId":"7097150","version":"1","preferredName":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain - Abemaciclib (Arm 5)","longName":"7097150","preferredDefinition":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain - Abemaciclib (Arm 5)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A002544-84B2-4776-E053-F662850ADF73","latestVersionIndicator":"Yes","beginDate":"2019-12-18","endDate":null,"createdBy":"PWEST","dateCreated":"2019-12-18","modifiedBy":"ONEDATA","dateModified":"2019-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87F5-3460-E053-4EBD850A1FCF","beginDate":"2019-12-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"TESTCreateNewPV","valueDescription":"Brain","ValueMeaning":{"publicId":"2558329","version":"1","preferredName":"Brain","longName":"2558329","preferredDefinition":"An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brain","conceptCode":"C12439","definition":"An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0E6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-87FF-3460-E053-4EBD850A1FCF","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain - Abemaciclib","valueDescription":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain - Abemaciclib","ValueMeaning":{"publicId":"7092664","version":"1","preferredName":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain - Abemaciclib","longName":"7092664","preferredDefinition":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain - Abemaciclib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D55FD6-5DF1-5461-E053-F662850AA6F6","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8809-3460-E053-4EBD850A1FCF","beginDate":"2019-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 6: AKT1/PIK3CA/PTEN mutation, Grade II/III - AZD5363 (Arm 4)","valueDescription":"Group 6: AKT1/PIK3CA/PTEN mutation, Grade II/III - AZD5363 (Arm 4)","ValueMeaning":{"publicId":"7092665","version":"1","preferredName":"Group 6: AKT1/PIK3CA/PTEN mutation, Grade II/III - AZD5363 (Arm 4)","longName":"7092665","preferredDefinition":"Group 6: AKT1/PIK3CA/PTEN mutation, Grade II/III - AZD5363 (Arm 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D55FD6-5E14-5461-E053-F662850AA6F6","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8813-3460-E053-4EBD850A1FCF","beginDate":"2019-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 5: AKT1/PIK3CA/PTEN mutation, Grade I - AZD5363 (Arm 4)","valueDescription":"Group 5: AKT1/PIK3CA/PTEN mutation, Grade I - AZD5363 (Arm 4)","ValueMeaning":{"publicId":"7092666","version":"1","preferredName":"Group 5: AKT1/PIK3CA/PTEN mutation, Grade I - AZD5363 (Arm 4)","longName":"7092666","preferredDefinition":"Group 5: AKT1/PIK3CA/PTEN mutation, Grade I - AZD5363 (Arm 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D55FD6-5E37-5461-E053-F662850AA6F6","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-881D-3460-E053-4EBD850A1FCF","beginDate":"2019-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 4: SMO/PTCH1 mutation, Grade II/III - Vismodegib (CLOSED for VIEWING 3/2/2018 - Arm 1)","valueDescription":"Group 4: SMO/PTCH1 mutation, Grade II/III - Vismodegib (CLOSED for VIEWING 3/2/2018 - Arm 1)","ValueMeaning":{"publicId":"7092667","version":"1","preferredName":"Group 4: SMO/PTCH1 mutation, Grade II/III - Vismodegib (CLOSED for VIEWING 3/2/2018 - Arm 1)","longName":"7092667","preferredDefinition":"Group 4: SMO/PTCH1 mutation, Grade II/III - Vismodegib (CLOSED for VIEWING 3/2/2018 - Arm 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D55FD6-5E5A-5461-E053-F662850AA6F6","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8827-3460-E053-4EBD850A1FCF","beginDate":"2019-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 3: SMO/PTCH1 mutation, Grade I - Vismodegib (CLOSED for VIEWING 3/2/2018 - Arm 1)","valueDescription":"Group 3: SMO/PTCH1 mutation, Grade I - Vismodegib (CLOSED for VIEWING 3/2/2018 - Arm 1)","ValueMeaning":{"publicId":"7092668","version":"1","preferredName":"Group 3: SMO/PTCH1 mutation, Grade I - Vismodegib (CLOSED for VIEWING 3/2/2018 - Arm 1)","longName":"7092668","preferredDefinition":"Group 3: SMO/PTCH1 mutation, Grade I - Vismodegib (CLOSED for VIEWING 3/2/2018 - Arm 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D55FD6-5E7D-5461-E053-F662850AA6F6","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8831-3460-E053-4EBD850A1FCF","beginDate":"2019-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 2: NF2 mutation, Grade II/III - GSK2256098 (CLOSED - Arm 2)","valueDescription":"Group 2: NF2 mutation, Grade II/III - GSK2256098 (CLOSED - Arm 2)","ValueMeaning":{"publicId":"7092669","version":"1","preferredName":"Group 2: NF2 mutation, Grade II/III - GSK2256098 (CLOSED - Arm 2)","longName":"7092669","preferredDefinition":"Group 2: NF2 mutation, Grade II/III - GSK2256098 (CLOSED - Arm 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D55FD6-5EA0-5461-E053-F662850AA6F6","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-883B-3460-E053-4EBD850A1FCF","beginDate":"2019-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 1: NF2 mutation, Grade I - GSK2256098 (CLOSED - Arm 2)","valueDescription":"Group 1: NF2 mutation, Grade I - GSK2256098 (CLOSED - Arm 2)","ValueMeaning":{"publicId":"7092670","version":"1","preferredName":"Group 1: NF2 mutation, Grade I - GSK2256098 (CLOSED - Arm 2)","longName":"7092670","preferredDefinition":"Group 1: NF2 mutation, Grade I - GSK2256098 (CLOSED - Arm 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D55FD6-5EC3-5461-E053-F662850AA6F6","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8845-3460-E053-4EBD850A1FCF","beginDate":"2019-12-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Bilateral salpingectomy","valueDescription":"Bilateral Salpingectomy","ValueMeaning":{"publicId":"6692824","version":"1","preferredName":"Bilateral Salpingectomy","longName":"6692824","preferredDefinition":"Surgery to remove part or all of both fallopian tubes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bilateral Salpingectomy","conceptCode":"C51667","definition":"Surgery to remove part or all of both fallopian tubes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869C83BB-0A7A-66E9-E053-F662850A3B6D","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-884F-3460-E053-4EBD850A1FCF","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Bilateral salpingo-oophorectomy","valueDescription":"Bilateral Salpingectomy with Oophorectomy","ValueMeaning":{"publicId":"4659456","version":"1","preferredName":"Bilateral Salpingectomy with Oophorectomy","longName":"4659456","preferredDefinition":"Surgery to remove both fallopian tubes, as well as both ovaries.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bilateral Salpingectomy with Oophorectomy","conceptCode":"C51765","definition":"Surgery to remove both fallopian tubes, as well as both ovaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C28F930-2FEC-4E7C-E050-BB89AD435548","latestVersionIndicator":"Yes","beginDate":"2015-01-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-01-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8859-3460-E053-4EBD850A1FCF","beginDate":"2019-10-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part III","valueDescription":"Part III","ValueMeaning":{"publicId":"7001591","version":"1","preferredName":"Part III","longName":"7001591","preferredDefinition":"Part III","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951CFD60-FC3A-069E-E053-F662850A43E9","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8863-3460-E053-4EBD850A1FCF","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part II","valueDescription":"Part II","ValueMeaning":{"publicId":"7001592","version":"1","preferredName":"Part II","longName":"7001592","preferredDefinition":"Part II","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951CFD60-FC5D-069E-E053-F662850A43E9","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-886D-3460-E053-4EBD850A1FCF","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Part I","valueDescription":"Part I","ValueMeaning":{"publicId":"7001593","version":"1","preferredName":"Part I","longName":"7001593","preferredDefinition":"Part I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"951CFD60-FC80-069E-E053-F662850A43E9","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8877-3460-E053-4EBD850A1FCF","beginDate":"2019-10-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 5: AKT1/PIK3CA/PTEN mutation, Grade I  AZD5363 (Arm 4)","valueDescription":"Group 5: AKT1/PIK3CA/PTEN mutation, Grade I  AZD5363 (Arm 4)","ValueMeaning":{"publicId":"7069439","version":"1","preferredName":"Group 5: AKT1/PIK3CA/PTEN mutation, Grade I  AZD5363 (Arm 4)","longName":"7069439","preferredDefinition":"Group 5: AKT1/PIK3CA/PTEN mutation, Grade I  AZD5363 (Arm 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B929E-F21F-0790-E053-F662850AD5A6","latestVersionIndicator":"Yes","beginDate":"2019-11-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-27","modifiedBy":"ONEDATA","dateModified":"2019-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8881-3460-E053-4EBD850A1FCF","beginDate":"2019-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain  Abemaciclib  (Arm 5)","valueDescription":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain  Abemaciclib  (Arm 5)","ValueMeaning":{"publicId":"7069437","version":"1","preferredName":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain  Abemaciclib  (Arm 5)","longName":"7069437","preferredDefinition":"Group 7: NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain  Abemaciclib  (Arm 5)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B929E-F1D9-0790-E053-F662850AD5A6","latestVersionIndicator":"Yes","beginDate":"2019-11-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-27","modifiedBy":"ONEDATA","dateModified":"2019-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-888B-3460-E053-4EBD850A1FCF","beginDate":"2019-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 6:AKT1/PIK3CA/PTEN mutation, Grade II/III  AZD5363 (Arm 4)","valueDescription":"Group 6:AKT1/PIK3CA/PTEN mutation, Grade II/III  AZD5363 (Arm 4)","ValueMeaning":{"publicId":"7069438","version":"1","preferredName":"Group 6:AKT1/PIK3CA/PTEN mutation, Grade II/III  AZD5363 (Arm 4)","longName":"7069438","preferredDefinition":"Group 6:AKT1/PIK3CA/PTEN mutation, Grade II/III  AZD5363 (Arm 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B929E-F1FC-0790-E053-F662850AD5A6","latestVersionIndicator":"Yes","beginDate":"2019-11-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-27","modifiedBy":"ONEDATA","dateModified":"2019-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8895-3460-E053-4EBD850A1FCF","beginDate":"2019-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 4: SMO/PTCH1 mutation, Grade II/III - Vismodegib (CLOSED for VIEWING 3/2/2018  Arm 1)","valueDescription":"Group 4: SMO/PTCH1 mutation, Grade II/III - Vismodegib (CLOSED for VIEWING 3/2/2018  Arm 1)","ValueMeaning":{"publicId":"7069440","version":"1","preferredName":"Group 4: SMO/PTCH1 mutation, Grade II/III - Vismodegib (CLOSED for VIEWING 3/2/2018  Arm 1)","longName":"7069440","preferredDefinition":"Group 4: SMO/PTCH1 mutation, Grade II/III - Vismodegib (CLOSED for VIEWING 3/2/2018  Arm 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B929E-F242-0790-E053-F662850AD5A6","latestVersionIndicator":"Yes","beginDate":"2019-11-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-27","modifiedBy":"ONEDATA","dateModified":"2019-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-889F-3460-E053-4EBD850A1FCF","beginDate":"2019-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 3: SMO/PTCH1 mutation, Grade I  Vismodegib (CLOSED for VIEWING 3/2/2018  Arm 1)","valueDescription":"Group 3: SMO/PTCH1 mutation, Grade I  Vismodegib (CLOSED for VIEWING 3/2/2018  Arm 1)","ValueMeaning":{"publicId":"7069441","version":"1","preferredName":"Group 3: SMO/PTCH1 mutation, Grade I  Vismodegib (CLOSED for VIEWING 3/2/2018  Arm 1)","longName":"7069441","preferredDefinition":"Group 3: SMO/PTCH1 mutation, Grade I  Vismodegib (CLOSED for VIEWING 3/2/2018  Arm 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B929E-F265-0790-E053-F662850AD5A6","latestVersionIndicator":"Yes","beginDate":"2019-11-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-27","modifiedBy":"ONEDATA","dateModified":"2019-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88A9-3460-E053-4EBD850A1FCF","beginDate":"2019-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 2: NF2 mutation, Grade II/III  GSK2256098 (CLOSED  Arm 2)","valueDescription":"Group 2: NF2 mutation, Grade II/III  GSK2256098 (CLOSED  Arm 2)","ValueMeaning":{"publicId":"7069442","version":"1","preferredName":"Group 2: NF2 mutation, Grade II/III  GSK2256098 (CLOSED  Arm 2)","longName":"7069442","preferredDefinition":"Group 2: NF2 mutation, Grade II/III  GSK2256098 (CLOSED  Arm 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B929E-F288-0790-E053-F662850AD5A6","latestVersionIndicator":"Yes","beginDate":"2019-11-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-27","modifiedBy":"ONEDATA","dateModified":"2019-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88B3-3460-E053-4EBD850A1FCF","beginDate":"2019-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 1: NF2 mutation, Grade I  GSK2256098 (CLOSED  Arm 2)","valueDescription":"Group 1: NF2 mutation, Grade I  GSK2256098 (CLOSED  Arm 2)","ValueMeaning":{"publicId":"7069443","version":"1","preferredName":"Group 1: NF2 mutation, Grade I  GSK2256098 (CLOSED  Arm 2)","longName":"7069443","preferredDefinition":"Group 1: NF2 mutation, Grade I  GSK2256098 (CLOSED  Arm 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B929E-F2AB-0790-E053-F662850AD5A6","latestVersionIndicator":"Yes","beginDate":"2019-11-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-27","modifiedBy":"ONEDATA","dateModified":"2019-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88BD-3460-E053-4EBD850A1FCF","beginDate":"2019-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Phase II - GBM Arm","valueDescription":"Phase II - GBM Arm","ValueMeaning":{"publicId":"7197430","version":"1","preferredName":"Phase II - GBM Arm","longName":"7197430","preferredDefinition":"Phase II - GBM Arm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A08462AB-D818-5D4E-E053-F662850ADF60","latestVersionIndicator":"Yes","beginDate":"2020-03-10","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-10","modifiedBy":"ONEDATA","dateModified":"2020-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88C7-3460-E053-4EBD850A1FCF","beginDate":"2020-03-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Phase II - Arm B","valueDescription":"Phase II - Arm B","ValueMeaning":{"publicId":"7197431","version":"1","preferredName":"Phase II - Arm B","longName":"7197431","preferredDefinition":"Phase II - Arm B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A08462AB-D83B-5D4E-E053-F662850ADF60","latestVersionIndicator":"Yes","beginDate":"2020-03-10","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-10","modifiedBy":"ONEDATA","dateModified":"2020-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88D1-3460-E053-4EBD850A1FCF","beginDate":"2020-03-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Phase II - Arm A","valueDescription":"Phase II - Arm A","ValueMeaning":{"publicId":"7197432","version":"1","preferredName":"Phase II - Arm A","longName":"7197432","preferredDefinition":"Phase II - Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A08462AB-D85E-5D4E-E053-F662850ADF60","latestVersionIndicator":"Yes","beginDate":"2020-03-10","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-10","modifiedBy":"ONEDATA","dateModified":"2020-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88DB-3460-E053-4EBD850A1FCF","beginDate":"2020-03-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Surgical Cohort","valueDescription":"Surgical Cohort","ValueMeaning":{"publicId":"7181297","version":"1","preferredName":"Surgical Cohort","longName":"7181297","preferredDefinition":"Surgical Cohort","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F044DBD-1011-0EA3-E053-F662850A98B1","latestVersionIndicator":"Yes","beginDate":"2020-02-20","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-20","modifiedBy":"ONEDATA","dateModified":"2020-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88E5-3460-E053-4EBD850A1FCF","beginDate":"2020-02-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Cohort 3","valueDescription":"Cohort 3","ValueMeaning":{"publicId":"2593323","version":"1","preferredName":"Cohort 3","longName":"2593323","preferredDefinition":"Cohort 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"288296AC-66E4-711B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88EF-3460-E053-4EBD850A1FCF","beginDate":"2020-02-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Cohort 2","valueDescription":"Cohort 2","ValueMeaning":{"publicId":"2593324","version":"1","preferredName":"Cohort 2: Patients with other DNA-repair genes tested in the FoudationOne panel excluding BRCA1, BRCA2, ATM, BAP1, MSH2, PALB2, and BRIP1 without high TMB","longName":"2593324v1.00","preferredDefinition":"Cohort 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"288296B4-61DB-7125-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-02-02","modifiedBy":"SOKKERL","dateModified":"2022-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-88F9-3460-E053-4EBD850A1FCF","beginDate":"2020-02-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Cohort 1","valueDescription":"Cohort 1","ValueMeaning":{"publicId":"2593325","version":"1","preferredName":"Cohort 1: Patients with BRCA1, BRCA2, ATM, BAP1, MSH2, PALB2, and BRIP1 or high TMB","longName":"2593325v1.00","preferredDefinition":"Cohort 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"288296BB-025C-712F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-02-02","modifiedBy":"SOKKERL","dateModified":"2022-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8903-3460-E053-4EBD850A1FCF","beginDate":"2020-02-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B: Non-Intervention (Standard Care)","valueDescription":"Arm B: Non-Intervention (Standard Care)","ValueMeaning":{"publicId":"7346759","version":"1","preferredName":"Arm B: Non-Intervention (Standard Care)","longName":"7346759","preferredDefinition":"Arm B: Non-Intervention (Standard Care)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9518AE9-3750-693A-E053-4EBD850ABBF6","latestVersionIndicator":"Yes","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-30","modifiedBy":"TAYLORT","dateModified":"2020-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-895C-3460-E053-4EBD850A1FCF","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A: Intervention (Intensive SBP Control)","valueDescription":"Arm A: Intervention (Intensive SBP Control)","ValueMeaning":{"publicId":"7346760","version":"1","preferredName":"Arm A: Intervention (Intensive SBP Control)","longName":"7346760","preferredDefinition":"Arm A: Intervention (Intensive SBP Control)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9518AE9-3773-693A-E053-4EBD850ABBF6","latestVersionIndicator":"Yes","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-30","modifiedBy":"TAYLORT","dateModified":"2020-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8948-3460-E053-4EBD850A1FCF","beginDate":"2020-06-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 3","valueDescription":"ARM 3","ValueMeaning":{"publicId":"2562141","version":"1","preferredName":"ARM 3","longName":"2562141","preferredDefinition":"ARM 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BFCA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-24","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-24","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FAD-3460-E053-4EBD850A1FCF","beginDate":"2002-07-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1","valueDescription":"ARM 1","ValueMeaning":{"publicId":"2562140","version":"1","preferredName":"ARM 1","longName":"2562140","preferredDefinition":"ARM 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BFC9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-24","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-24","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FB7-3460-E053-4EBD850A1FCF","beginDate":"2002-07-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2","valueDescription":"Arm 2","ValueMeaning":{"publicId":"2570937","version":"1","preferredName":"Arm 2","longName":"2570937","preferredDefinition":"Arm 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E226-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-06-25","modifiedBy":"CAMPBELB","dateModified":"2004-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FC1-3460-E053-4EBD850A1FCF","beginDate":"2004-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX)","valueDescription":"Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX)","ValueMeaning":{"publicId":"2571169","version":"1","preferredName":"Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX)","longName":"2571169","preferredDefinition":"Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E30E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"CAMPBELB","dateModified":"2004-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FCB-3460-E053-4EBD850A1FCF","beginDate":"2004-07-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Irinotecan + 5-Fluorouracil/Leucovorin Regimen (FOLFIRI)","valueDescription":"Irinotecan + 5-Fluorouracil/Leucovorin Regimen (FOLFIRI)","ValueMeaning":{"publicId":"2571170","version":"1","preferredName":"Irinotecan + 5-Fluorouracil/Leucovorin Regimen (FOLFIRI)","longName":"2571170","preferredDefinition":"Irinotecan + 5-Fluorouracil/Leucovorin Regimen (FOLFIRI)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E30F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"CAMPBELB","dateModified":"2004-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FD5-3460-E053-4EBD850A1FCF","beginDate":"2004-07-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"FOLFOX + FOLFIRI (Hybrid Regimen)","valueDescription":"FOLFOX + FOLFIRI (Hybrid Regimen)","ValueMeaning":{"publicId":"2571171","version":"1","preferredName":"FOLFOX + FOLFIRI (Hybrid Regimen)","longName":"2571171","preferredDefinition":"FOLFOX + FOLFIRI (Hybrid Regimen)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E310-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"CAMPBELB","dateModified":"2004-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FDF-3460-E053-4EBD850A1FCF","beginDate":"2004-07-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX) + C225","valueDescription":"Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX) + C225","ValueMeaning":{"publicId":"2571172","version":"1","preferredName":"Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX) + C225","longName":"2571172","preferredDefinition":"Oxaliplatin + Fluorouracil/Leucovorin Regimen (FOLFOX) + C225","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E311-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"CAMPBELB","dateModified":"2004-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FE9-3460-E053-4EBD850A1FCF","beginDate":"2004-07-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Irinotecan + 5-Fluorouracil/Leucovorin Regimen (FOLFIRI) + C225","valueDescription":"Irinotecan + 5-Fluorouracil/Leucovorin Regimen (FOLFIRI) + C225","ValueMeaning":{"publicId":"2571173","version":"1","preferredName":"Irinotecan + 5-Fluorouracil/Leucovorin Regimen (FOLFIRI) + C225","longName":"2571173","preferredDefinition":"Irinotecan + 5-Fluorouracil/Leucovorin Regimen (FOLFIRI) + C225","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E312-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"CAMPBELB","dateModified":"2004-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FF3-3460-E053-4EBD850A1FCF","beginDate":"2004-07-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"FOLFOX + FOLFIRI (Hybrid Regimen) + 225","valueDescription":"FOLFOX + FOLFIRI (Hybrid Regimen) + 225","ValueMeaning":{"publicId":"2571174","version":"1","preferredName":"FOLFOX + FOLFIRI (Hybrid Regimen) + 225","longName":"2571174","preferredDefinition":"FOLFOX + FOLFIRI (Hybrid Regimen) + 225","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E313-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"CAMPBELB","dateModified":"2004-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-7FFD-3460-E053-4EBD850A1FCF","beginDate":"2004-07-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 4","valueDescription":"Arm 4","ValueMeaning":{"publicId":"2572245","version":"1","preferredName":"Arm 4","longName":"2572245","preferredDefinition":"Treatment Arm #4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E742-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-18","modifiedBy":"CAMPBELB","dateModified":"2004-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8007-3460-E053-4EBD850A1FCF","beginDate":"2004-11-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A","valueDescription":"Arm A","ValueMeaning":{"publicId":"2571806","version":"1","preferredName":"Arm A","longName":"2571806","preferredDefinition":"Treatment Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E58B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-08","modifiedBy":"CAMPBELB","dateModified":"2004-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8011-3460-E053-4EBD850A1FCF","beginDate":"2004-09-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B","valueDescription":"Arm B","ValueMeaning":{"publicId":"2571807","version":"1","preferredName":"Arm B","longName":"2571807","preferredDefinition":"Treatment Arm B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E58C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-08","modifiedBy":"CAMPBELB","dateModified":"2004-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-801B-3460-E053-4EBD850A1FCF","beginDate":"2004-09-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 1: Whole Breast Irradiation","valueDescription":"Group 1: Whole Breast Irradiation","ValueMeaning":{"publicId":"2572041","version":"1","preferredName":"Group 1: Whole Breast Irradiation","longName":"2572041","preferredDefinition":"Group 1: Whole Breast Irradiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E676-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-21","modifiedBy":"CAMPBELB","dateModified":"2004-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8025-3460-E053-4EBD850A1FCF","beginDate":"2004-10-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 2: Partial Breast Irradiation","valueDescription":"Group 2: Partial Breast Irradiation","ValueMeaning":{"publicId":"2572040","version":"1","preferredName":"Group 2: Partial Breast Irradiation","longName":"2572040","preferredDefinition":"Group 2: Partial Breast Irradiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E675-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-21","modifiedBy":"CAMPBELB","dateModified":"2004-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-802F-3460-E053-4EBD850A1FCF","beginDate":"2004-10-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Induction chemo alone","valueDescription":"Induction chemo alone","ValueMeaning":{"publicId":"2571957","version":"1","preferredName":"Induction chemo alone","longName":"2571957","preferredDefinition":"Induction chemotherapy alone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E622-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-21","modifiedBy":"CAMPBELB","dateModified":"2004-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8039-3460-E053-4EBD850A1FCF","beginDate":"2004-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Induction chemo / XRT","valueDescription":"Induction chemo / XRT","ValueMeaning":{"publicId":"2571958","version":"1","preferredName":"Induction chemo / XRT","longName":"2571958","preferredDefinition":"Induction chemotherapy / XRT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E623-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-21","modifiedBy":"CAMPBELB","dateModified":"2004-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8043-3460-E053-4EBD850A1FCF","beginDate":"2004-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Pre-register","valueDescription":"Pre-register","ValueMeaning":{"publicId":"2574349","version":"1","preferredName":"Pre-register","longName":"2574349","preferredDefinition":"Pre-register","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF7A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-08","modifiedBy":"CAMPBELB","dateModified":"2005-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-804D-3460-E053-4EBD850A1FCF","beginDate":"2005-04-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Oxaliplatin/Leucovorin/5-FU","valueDescription":"Oxaliplatin/Leucovorin/5-FU","ValueMeaning":{"publicId":"2573157","version":"1","preferredName":"Oxaliplatin/Leucovorin/5-FU","longName":"2573157","preferredDefinition":"Oxaliplatin/Leucovorin/5-FU","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAD2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-02-11","modifiedBy":"SHIDED","dateModified":"2005-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8057-3460-E053-4EBD850A1FCF","beginDate":"2005-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Oxaliplatin/Leucovorin/5-FU/Bevacizumab","valueDescription":"Oxaliplatin/Leucovorin/5-FU/Bevacizumab","ValueMeaning":{"publicId":"2573158","version":"1","preferredName":"Oxaliplatin/Leucovorin/5-FU/Bevacizumab","longName":"2573158","preferredDefinition":"Oxaliplatin/Leucovorin/5-FU/Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAD3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-02-11","modifiedBy":"SHIDED","dateModified":"2005-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8061-3460-E053-4EBD850A1FCF","beginDate":"2005-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Anastrozole","valueDescription":"ANASTROZOLE","ValueMeaning":{"publicId":"2561407","version":"1","preferredName":"ANASTROZOLE","longName":"2561407","preferredDefinition":"ANASTROZOLE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCEC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-806B-3460-E053-4EBD850A1FCF","beginDate":"2005-08-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Anastrozole/fulvestrant","valueDescription":"Anastrozole/fulvestrant","ValueMeaning":{"publicId":"2575942","version":"1","preferredName":"Anastrozole/fulvestrant","longName":"2575942","preferredDefinition":"Anastrozole/fulvestrant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"CAMPBELB","dateModified":"2005-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8075-3460-E053-4EBD850A1FCF","beginDate":"2005-08-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Fulvestrant","valueDescription":"Fulvestrant","ValueMeaning":{"publicId":"2575943","version":"1","preferredName":"Fulvestrant","longName":"2575943","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-807F-3460-E053-4EBD850A1FCF","beginDate":"2005-08-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1: Anastrozole only","valueDescription":"Arm 1: Anastrozole only","ValueMeaning":{"publicId":"2578622","version":"1","preferredName":"Arm 1: Anastrozole only","longName":"2578622","preferredDefinition":"Arm 1: Anastrozole only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-002B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-04-07","modifiedBy":"CAMPBELB","dateModified":"2006-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8089-3460-E053-4EBD850A1FCF","beginDate":"2006-04-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2: Anastrozole and fulvestrant","valueDescription":"Arm 2: Anastrozole and fulvestrant","ValueMeaning":{"publicId":"2578623","version":"1","preferredName":"Arm 2: Anastrozole and fulvestrant","longName":"2578623","preferredDefinition":"Arm 2: Anastrozole and fulvestrant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-002C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-04-07","modifiedBy":"CAMPBELB","dateModified":"2006-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8093-3460-E053-4EBD850A1FCF","beginDate":"2006-04-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1: Octreotide + Bevacizumab","valueDescription":"Arm 1: Octreotide + Bevacizumab","ValueMeaning":{"publicId":"2578349","version":"1","preferredName":"Arm 1: Octreotide + Bevacizumab","longName":"2578349","preferredDefinition":"Arm 1: Octreotide + Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF1A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-17","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-809D-3460-E053-4EBD850A1FCF","beginDate":"2006-03-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1: Octreotide + Interferon alpha 2b","valueDescription":"Arm 1: Octreotide + Interferon alpha 2b","ValueMeaning":{"publicId":"2578348","version":"1","preferredName":"Arm 1: Octreotide + Interferon alpha 2b","longName":"2578348","preferredDefinition":"Arm 1: Octreotide + Interferon alpha 2b","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF19-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-17","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80A7-3460-E053-4EBD850A1FCF","beginDate":"2006-03-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 1A, 2A, or 3A","valueDescription":"Group 1A, 2A, or 3A","ValueMeaning":{"publicId":"2580614","version":"1","preferredName":"Group 1A, 2A, or 3A","longName":"2580614","preferredDefinition":"Group 1A, 2A, or 3A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-07F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-23","modifiedBy":"ALAIS","dateModified":"2006-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80B1-3460-E053-4EBD850A1FCF","beginDate":"2006-08-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Group 1B, 2B, or 3B","valueDescription":"Group 1B, 2B, or 3B","ValueMeaning":{"publicId":"2580615","version":"1","preferredName":"Group 1B, 2B, or 3B","longName":"2580615","preferredDefinition":"Group 1B, 2B, or 3B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-07F4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-23","modifiedBy":"ALAIS","dateModified":"2006-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80BB-3460-E053-4EBD850A1FCF","beginDate":"2006-08-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1: Cetuximab","valueDescription":"Arm 1: Cetuximab","ValueMeaning":{"publicId":"2582918","version":"1","preferredName":"Arm 1: Cetuximab","longName":"2582918","preferredDefinition":"Arm 1: Cetuximab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2582F5D0-DE73-62EA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-12-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80C5-3460-E053-4EBD850A1FCF","beginDate":"2006-12-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2: Cetuximab + lower-dose bevacizumab","valueDescription":"Arm 2: Cetuximab + lower-dose bevacizumab","ValueMeaning":{"publicId":"2582920","version":"1","preferredName":"Arm 2: Cetuximab + lower-dose bevacizumab","longName":"2582920","preferredDefinition":"Arm 2: Cetuximab + lower-dose bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2582FA90-43B2-5A2E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-12-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80CF-3460-E053-4EBD850A1FCF","beginDate":"2006-12-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 3: Cetuximab + higher-dose bevacizumab","valueDescription":"Arm 3: Cetuximab + higher-dose bevacizumab","ValueMeaning":{"publicId":"2582921","version":"1","preferredName":"Arm 3: Cetuximab + higher-dose bevacizumab","longName":"2582921","preferredDefinition":"Arm 3: Cetuximab + higher-dose bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2582FC43-87F6-496D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-12-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80D9-3460-E053-4EBD850A1FCF","beginDate":"2006-12-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A: FOLFOX or FOLFIRI plus Bevacizumab","valueDescription":"Arm A: FOLFOX or FOLFIRI plus Bevacizumab","ValueMeaning":{"publicId":"2672459","version":"1","preferredName":"Arm A: FOLFOX or FOLFIRI plus Bevacizumab","longName":"2672459","preferredDefinition":"Arm A: FOLFOX or FOLFIRI plus Bevacizumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37AA4AC7-9704-53B7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80E3-3460-E053-4EBD850A1FCF","beginDate":"2007-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B: FOLFOX or FOLFIRI plus Cetuximab","valueDescription":"Arm B: FOLFOX or FOLFIRI plus Cetuximab","ValueMeaning":{"publicId":"2672460","version":"1","preferredName":"Arm B: FOLFOX or FOLFIRI plus Cetuximab","longName":"2672460","preferredDefinition":"Arm B: FOLFOX or FOLFIRI plus Cetuximab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37AA4C2F-8F42-5B7C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80ED-3460-E053-4EBD850A1FCF","beginDate":"2007-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm C: FOLFOX or FOLFIRI plus Bevacizumab and Cetuximab","valueDescription":"Arm C: FOLFOX or FOLFIRI plus Bevacizumab and Cetuximab","ValueMeaning":{"publicId":"2672461","version":"1","preferredName":"Arm C: FOLFOX or FOLFIRI plus Bevacizumab and Cetuximab","longName":"2672461","preferredDefinition":"Arm C: FOLFOX or FOLFIRI plus Bevacizumab and Cetuximab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37AA4D7F-9CB1-5AA7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-80F7-3460-E053-4EBD850A1FCF","beginDate":"2007-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Letrozole","valueDescription":"LETROZOLE","ValueMeaning":{"publicId":"2561408","version":"1","preferredName":"LETROZOLE","longName":"2561408","preferredDefinition":"LETROZOLE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8101-3460-E053-4EBD850A1FCF","beginDate":"2007-05-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"TAMOXIFEN","ValueMeaning":{"publicId":"2561706","version":"1","preferredName":"TAMOXIFEN","longName":"2561706","preferredDefinition":"TAMOXIFEN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE17-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-810B-3460-E053-4EBD850A1FCF","beginDate":"2007-05-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Wedge resection","valueDescription":"Wedge Resection","ValueMeaning":{"publicId":"2570806","version":"1","preferredName":"Wedge Resection","longName":"2570806v1.00","preferredDefinition":"Surgical removal of a triangular wedge shaped section of tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wedge Excision","conceptCode":"C51690","definition":"Surgical removal of a triangular wedge shaped section of tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E1A3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8115-3460-E053-4EBD850A1FCF","beginDate":"2007-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Lobectomy","valueDescription":"Lobectomy","ValueMeaning":{"publicId":"2566494","version":"1","preferredName":"Lobectomy","longName":"2566494","preferredDefinition":"(lo-BEK-toe-mee) The removal of a lobe.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lobectomy","conceptCode":"C15272","definition":"Surgical removal of a lobe of an organ.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D0CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-11","endDate":null,"createdBy":"DWARZEL","dateCreated":"2003-08-11","modifiedBy":"LEEB","dateModified":"2008-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-811F-3460-E053-4EBD850A1FCF","beginDate":"2007-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Patient not randomized","valueDescription":"Patient not randomized","ValueMeaning":{"publicId":"2639297","version":"1","preferredName":"Patient not randomized","longName":"2639297","preferredDefinition":"Patient not randomized","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"30B25838-D1E1-15BE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8129-3460-E053-4EBD850A1FCF","beginDate":"2007-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Trastuzumab alone","valueDescription":"Trastuzumab","ValueMeaning":{"publicId":"2576422","version":"1","preferredName":"Trastuzumab","longName":"2576422","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F793-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8133-3460-E053-4EBD850A1FCF","beginDate":"2007-06-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Lapatinib alone","valueDescription":"Lapatinib","ValueMeaning":{"publicId":"2647015","version":"1","preferredName":"Lapatinib","longName":"2647015","preferredDefinition":"The ditosylate salt of a synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapatinib","conceptCode":"C26653","definition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3229BE13-DB27-00BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-813D-3460-E053-4EBD850A1FCF","beginDate":"2007-06-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Trastuzumab followed by Lapatinib","valueDescription":"Trastuzumab followed by Lapatinib","ValueMeaning":{"publicId":"2647016","version":"1","preferredName":"Trastuzumab followed by Lapatinib","longName":"2647016","preferredDefinition":"Trastuzumab followed by Lapatinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3229B0B8-9915-7329-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8147-3460-E053-4EBD850A1FCF","beginDate":"2007-06-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Lapatinib in combination with Trastuzumab","valueDescription":"Lapatinib in combination with Trastuzumab","ValueMeaning":{"publicId":"2647017","version":"1","preferredName":"Lapatinib in combination with Trastuzumab","longName":"2647017","preferredDefinition":"Lapatinib in combination with Trastuzumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3229C358-317B-74D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8151-3460-E053-4EBD850A1FCF","beginDate":"2007-06-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm C","valueDescription":"Arm C","ValueMeaning":{"publicId":"2683536","version":"1","preferredName":"Arm C","longName":"2683536","preferredDefinition":"Arm C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAA63E8-3CE8-67CA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-815B-3460-E053-4EBD850A1FCF","beginDate":"2007-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm D","valueDescription":"Arm D","ValueMeaning":{"publicId":"2683537","version":"1","preferredName":"Arm D","longName":"2683537","preferredDefinition":"Arm D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAA6536-50B1-6951-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8165-3460-E053-4EBD850A1FCF","beginDate":"2007-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm E","valueDescription":"Arm E","ValueMeaning":{"publicId":"2683538","version":"1","preferredName":"Arm E","longName":"2683538","preferredDefinition":"Arm E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAA65D4-A11A-67C8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-816F-3460-E053-4EBD850A1FCF","beginDate":"2007-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm F","valueDescription":"Arm F","ValueMeaning":{"publicId":"2683539","version":"1","preferredName":"Arm F","longName":"2683539","preferredDefinition":"Arm F","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAA6536-50C1-6951-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8179-3460-E053-4EBD850A1FCF","beginDate":"2007-09-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"CA Therapy -- 4 cycles (C-600 mg/m2 A-60 mg/m2 q-14 days)","valueDescription":"CA Therapy -- 4 cycles (C-600 mg/m2 A-60 mg/m2 q-14 days)","ValueMeaning":{"publicId":"2670904","version":"1","preferredName":"CA Therapy -- 4 cycles (C-600 mg/m2 A-60 mg/m2 q-14 days)","longName":"2670904","preferredDefinition":"CA Therapy -- 4 cycles (C-600 mg/m2 A-60 mg/m2 q-14 days)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36BB0357-D6AF-731E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8183-3460-E053-4EBD850A1FCF","beginDate":"2007-08-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"CA Therapy -- 6 cycles (C-600 mg/m2 A-60 mg/m2 q-14 days)","valueDescription":"CA Therapy -- 6 cycles (C-600 mg/m2 A-60 mg/m2 q-14 days)","ValueMeaning":{"publicId":"2670905","version":"1","preferredName":"CA Therapy -- 6 cycles (C-600 mg/m2 A-60 mg/m2 q-14 days)","longName":"2670905","preferredDefinition":"CA Therapy -- 6 cycles (C-600 mg/m2 A-60 mg/m2 q-14 days)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36BB0496-2271-0C3A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-818D-3460-E053-4EBD850A1FCF","beginDate":"2007-08-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Paclitaxel -- 4 cycles (175 mg/m2 q-14 days)","valueDescription":"Paclitaxel -- 4 cycles (175 mg/m2 q-14 days)","ValueMeaning":{"publicId":"2670906","version":"1","preferredName":"Paclitaxel -- 4 cycles (175 mg/m2 q-14 days)","longName":"2670906","preferredDefinition":"Paclitaxel -- 4 cycles (175 mg/m2 q-14 days)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36BB0B37-0A1E-0D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8197-3460-E053-4EBD850A1FCF","beginDate":"2007-08-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Paclitaxel -- 6 cycles (175 mg/m2 q-14 days)","valueDescription":"Paclitaxel -- 6 cycles (175 mg/m2 q-14 days)","ValueMeaning":{"publicId":"2670907","version":"1","preferredName":"Paclitaxel -- 6 cycles (175 mg/m2 q-14 days)","longName":"2670907","preferredDefinition":"Paclitaxel -- 6 cycles (175 mg/m2 q-14 days)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36BB0C58-6E34-0BEA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-08-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81A1-3460-E053-4EBD850A1FCF","beginDate":"2007-08-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1: Paclitaxel + Trastuzumab + Lapatinib","valueDescription":"Arm 1: Paclitaxel + Trastuzumab + Lapatinib","ValueMeaning":{"publicId":"2680505","version":"1","preferredName":"Arm 1: Paclitaxel + Trastuzumab + Lapatinib","longName":"2680505","preferredDefinition":"Arm 1: Paclitaxel + Trastuzumab + Lapatinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E0AEAA-57F3-3160-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81AB-3460-E053-4EBD850A1FCF","beginDate":"2007-09-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2: Paclitaxel + Trastuzumab","valueDescription":"Arm 2: Paclitaxel + Trastuzumab","ValueMeaning":{"publicId":"2680506","version":"1","preferredName":"Arm 2: Paclitaxel + Trastuzumab","longName":"2680506","preferredDefinition":"Arm 2: Paclitaxel + Trastuzumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E0B22A-1B0C-298E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81B5-3460-E053-4EBD850A1FCF","beginDate":"2007-09-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 3: Paclitaxel + Lapatinib","valueDescription":"Arm 3: Paclitaxel + Lapatinib","ValueMeaning":{"publicId":"2680509","version":"1","preferredName":"Arm 3: Paclitaxel + Lapatinib","longName":"2680509","preferredDefinition":"Arm 3: Paclitaxel + Lapatinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E0B385-55C4-3A28-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81BF-3460-E053-4EBD850A1FCF","beginDate":"2007-09-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm A: Early treatment with Rituximab + Fludarabine","valueDescription":"Arm A: Early treatment with Rituximab + Fludarabine","ValueMeaning":{"publicId":"2663890","version":"1","preferredName":"Arm A: Early treatment with Rituximab + Fludarabine","longName":"2663890","preferredDefinition":"Arm A: Early treatment with Rituximab + Fludarabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3511FB49-E22C-5A0C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81C9-3460-E053-4EBD850A1FCF","beginDate":"2007-07-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm B: Observation with later treatment with Rituximab + Fludarabine","valueDescription":"Arm B: Observation with later treatment with Rituximab + Fludarabine","ValueMeaning":{"publicId":"2663889","version":"1","preferredName":"Arm B: Observation with later treatment with Rituximab + Fludarabine","longName":"2663889","preferredDefinition":"Arm B: Observation with later treatment with Rituximab + Fludarabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3511F907-7E07-5A10-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81D3-3460-E053-4EBD850A1FCF","beginDate":"2007-07-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm C: Follow up until NC196 criteria met; the patient receives Rituximab + Fludarabine or other alternative treatment per physician","valueDescription":"Arm C: Follow up until NC196 criteria met; the patient receives Rituximab + Fludarabine or other alternative treatment per physician","ValueMeaning":{"publicId":"2663888","version":"1","preferredName":"Arm C: Follow up until NC196 criteria met; the patient receives Rituximab + Fludarabine or other alternative treatment per physician","longName":"2663888","preferredDefinition":"Arm C: Follow up until NC196 criteria met; the patient receives Rituximab + Fludarabine or other alternative treatment per physician","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3511F622-39FD-5E4B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81DD-3460-E053-4EBD850A1FCF","beginDate":"2007-07-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2, Cisplatin / Paclitaxel","valueDescription":"Arm 2, Cisplatin / Paclitaxel","ValueMeaning":{"publicId":"2572575","version":"1","preferredName":"Arm 2, Cisplatin / Paclitaxel","longName":"2572575","preferredDefinition":"Arm 2, Cisplatin / Paclitaxel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E88C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-12-30","modifiedBy":"SHIDED","dateModified":"2004-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81E7-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2, Cisplatin / Docetaxel","valueDescription":"Arm 2, Cisplatin / Docetaxel","ValueMeaning":{"publicId":"2572576","version":"1","preferredName":"Arm 2, Cisplatin / Docetaxel","longName":"2572576","preferredDefinition":"Arm 2, Cisplatin / Docetaxel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E88D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-12-30","modifiedBy":"SHIDED","dateModified":"2004-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81F1-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 2, Cisplatin / 5-FU","valueDescription":"Arm 2, Cisplatin / 5-FU","ValueMeaning":{"publicId":"2572574","version":"1","preferredName":"Arm 2, Cisplatin / 5-FU","longName":"2572574","preferredDefinition":"Arm 2, Cisplatin / 5-FU","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E88B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-12-30","modifiedBy":"SHIDED","dateModified":"2004-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-81FB-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Arm 1, RT plus Cisplatin / Paclitaxel","valueDescription":"Arm 1, RT plus Cisplatin / Paclitaxel","ValueMeaning":{"publicId":"2572573","version":"1","preferredName":"Arm 1, RT plus Cisplatin / Paclitaxel","longName":"2572573","preferredDefinition":"Arm 1, RT plus Cisplatin / Paclitaxel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E88A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-12-30","modifiedBy":"SHIDED","dateModified":"2004-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8205-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"TAC","valueDescription":"Cyclophosphamide Docetaxel Doxorubicin","ValueMeaning":{"publicId":"2730957","version":"1","preferredName":"Cyclophosphamide Docetaxel Doxorubicin","longName":"2730957","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46C22121-67B6-63D5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-820F-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Radiation therapy + trastuzumab","valueDescription":"Trastuzumab Radiation Therapy","ValueMeaning":{"publicId":"2730958","version":"1","preferredName":"Trastuzumab Radiation Therapy","longName":"2730958","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI): use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46C22121-67E2-63D5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB82EBDA-8219-3460-E053-4EBD850A1FCF","beginDate":"2008-02-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"Pembrolizumab alone","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE316A71-2592-2CD2-E053-4EBD850ADF81","beginDate":"2020-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-31","modifiedBy":"ONEDATA","dateModified":"2020-08-31","deletedIndicator":"No"},{"value":"Pembrolizumab + Chemotherapy","valueDescription":"Chemotherapy And Pembrolizumab","ValueMeaning":{"publicId":"7410726","version":"1","preferredName":"Chemotherapy And Pembrolizumab","longName":"7410726","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE316A71-25A0-2CD2-E053-4EBD850ADF81","latestVersionIndicator":"Yes","beginDate":"2020-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-31","modifiedBy":"ONEDATA","dateModified":"2020-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE316A71-25B9-2CD2-E053-4EBD850ADF81","beginDate":"2020-08-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-31","modifiedBy":"ONEDATA","dateModified":"2020-08-31","deletedIndicator":"No"},{"value":"Group 4: Vismodegib - SMO/PTCH1 mutation, Grade II/III - (CLOSED for VIEWING 3/2/2018)","valueDescription":"Group 4: Vismodegib - SMO/PTCH1 mutation, Grade II/III - (CLOSED for VIEWING 3/2/2018)","ValueMeaning":{"publicId":"7539766","version":"1","preferredName":"Group 4: Vismodegib - SMO/PTCH1 mutation, Grade II/III - (CLOSED for VIEWING 3/2/2018)","longName":"7539766","preferredDefinition":"Group 4: Vismodegib - SMO/PTCH1 mutation, Grade II/III - (CLOSED for VIEWING 3/2/2018)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B78889DE-102F-1DDD-E053-4EBD850A9562","latestVersionIndicator":"Yes","beginDate":"2020-12-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-28","modifiedBy":"ONEDATA","dateModified":"2020-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B78889DE-1048-1DDD-E053-4EBD850A9562","beginDate":"2020-12-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-28","modifiedBy":"ONEDATA","dateModified":"2020-12-28","deletedIndicator":"No"},{"value":"Group 3: Vismodegib - SMO/PTCH1 mutation, Grade I  (CLOSED for VIEWING 3/2/2018)","valueDescription":"Group 3: Vismodegib - SMO/PTCH1 mutation, Grade I  (CLOSED for VIEWING 3/2/2018)","ValueMeaning":{"publicId":"7539711","version":"1","preferredName":"Group 3: Vismodegib - SMO/PTCH1 mutation, Grade I  (CLOSED for VIEWING 3/2/2018)","longName":"7539711","preferredDefinition":"Group 3: Vismodegib - SMO/PTCH1 mutation, Grade I  (CLOSED for VIEWING 3/2/2018)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B726FAAB-4DEF-4740-E053-4EBD850AF5EA","latestVersionIndicator":"Yes","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B78889DE-105C-1DDD-E053-4EBD850A9562","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-28","modifiedBy":"ONEDATA","dateModified":"2020-12-28","deletedIndicator":"No"},{"value":"Group 7: Abemaciclib - NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain","valueDescription":"Group 7: Abemaciclib - NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain","ValueMeaning":{"publicId":"7539707","version":"1","preferredName":"Group 7: Abemaciclib - NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain","longName":"7539707","preferredDefinition":"Group 7: Abemaciclib - NF2 mutation/CDKN2A copy number loss/CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B726FAAB-4D63-4740-E053-4EBD850AF5EA","latestVersionIndicator":"Yes","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B726FAAB-4D7C-4740-E053-4EBD850AF5EA","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","deletedIndicator":"No"},{"value":"Group 6: Capivasertib - AKT1/PIK3CA/PTEN mutation, Grade II/III","valueDescription":"Group 6: Capivasertib - AKT1/PIK3CA/PTEN mutation, Grade II/III","ValueMeaning":{"publicId":"7539708","version":"1","preferredName":"Group 6: Capivasertib - AKT1/PIK3CA/PTEN mutation, Grade II/III","longName":"7539708","preferredDefinition":"Group 6: Capivasertib - AKT1/PIK3CA/PTEN mutation, Grade II/III","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B726FAAB-4D86-4740-E053-4EBD850AF5EA","latestVersionIndicator":"Yes","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B726FAAB-4D9F-4740-E053-4EBD850AF5EA","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","deletedIndicator":"No"},{"value":"Group 5: Capivasertib - AKT1/PIK3CA/PTEN mutation, Grade I","valueDescription":"Group 5: Capivasertib - AKT1/PIK3CA/PTEN mutation, Grade I","ValueMeaning":{"publicId":"7539709","version":"1","preferredName":"Group 5: Capivasertib - AKT1/PIK3CA/PTEN mutation, Grade I","longName":"7539709","preferredDefinition":"Group 5: Capivasertib - AKT1/PIK3CA/PTEN mutation, Grade I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B726FAAB-4DA9-4740-E053-4EBD850AF5EA","latestVersionIndicator":"Yes","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B726FAAB-4DC2-4740-E053-4EBD850AF5EA","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","deletedIndicator":"No"},{"value":"Group 2: GSK2256098 - NF2 mutation, Grade II/III  (CLOSED)","valueDescription":"Group 2: GSK2256098 - NF2 mutation, Grade II/III  (CLOSED)","ValueMeaning":{"publicId":"7539712","version":"1","preferredName":"Group 2: GSK2256098 - NF2 mutation, Grade II/III  (CLOSED)","longName":"7539712","preferredDefinition":"Group 2: GSK2256098 - NF2 mutation, Grade II/III  (CLOSED)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B726FAAB-4E12-4740-E053-4EBD850AF5EA","latestVersionIndicator":"Yes","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B726FAAB-4E2B-4740-E053-4EBD850AF5EA","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","deletedIndicator":"No"},{"value":"Group 1: GSK2256098 - NF2 mutation, Grade I  (CLOSED)","valueDescription":"Group 1: GSK2256098 - NF2 mutation, Grade I  (CLOSED)","ValueMeaning":{"publicId":"7539713","version":"1","preferredName":"Group 1: GSK2256098 - NF2 mutation, Grade I  (CLOSED)","longName":"7539713","preferredDefinition":"Group 1: GSK2256098 - NF2 mutation, Grade I  (CLOSED)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B726FAAB-4E35-4740-E053-4EBD850AF5EA","latestVersionIndicator":"Yes","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B726FAAB-4E4E-4740-E053-4EBD850AF5EA","beginDate":"2020-12-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-23","modifiedBy":"ONEDATA","dateModified":"2020-12-23","deletedIndicator":"No"},{"value":"Obeticholic Acid 25mg","valueDescription":"Obeticholic Acid","ValueMeaning":{"publicId":"7515884","version":"1","preferredName":"Obeticholic Acid","longName":"7515884v1.00","preferredDefinition":"An orally bioavailable semi-synthetic bile acid derivative and an agonist of the nuclear bile acid receptor farnesoid X receptor (FXR) that may be used to lower hepatic exposure to bile acids. Upon oral administration, obeticholic acid targets and binds to FXR expressed in the liver and intestine, activating FXR-mediated bile acid, inflammatory, fibrotic, and metabolic pathways. This suppresses the production of bile acid in the hepatocytes and increases bile acid transport out of the hepatocytes, thereby reducing hepatic exposure to bile acids. FXR plays an important role in bile acid homeostasis and is involved in hepatic and intestinal inflammation and liver fibrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obeticholic Acid","conceptCode":"C80837","definition":"An orally bioavailable semi-synthetic bile acid derivative and an agonist of the nuclear bile acid receptor farnesoid X receptor (FXR) that may be used to lower hepatic exposure to bile acids. Upon oral administration, obeticholic acid targets and binds to FXR expressed in the liver and intestine, activating FXR-mediated bile acid, inflammatory, fibrotic, and metabolic pathways. This suppresses the production of bile acid in the hepatocytes and increases bile acid transport out of the hepatocytes, thereby reducing hepatic exposure to bile acids. FXR plays an important role in bile acid homeostasis and is involved in hepatic and intestinal inflammation and liver fibrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4DF60D8-512E-12FF-E053-4EBD850A9790","latestVersionIndicator":"Yes","beginDate":"2020-11-24","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2020-11-24","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6FC9369-E1E2-4890-E053-4EBD850A372B","beginDate":"2020-12-21","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2020-12-21","modifiedBy":"ONEDATA","dateModified":"2020-12-21","deletedIndicator":"No"},{"value":"Placebo","valueDescription":"Placebo","ValueMeaning":{"publicId":"3228305","version":"1","preferredName":"Placebo","longName":"3228305","preferredDefinition":"An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B5D-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6FC9369-E1EC-4890-E053-4EBD850A372B","beginDate":"2020-12-21","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2020-12-21","modifiedBy":"ONEDATA","dateModified":"2020-12-21","deletedIndicator":"No"},{"value":"Oxybutynin 5.0 mL","valueDescription":"Oxybutynin 5.0 mL","ValueMeaning":{"publicId":"7634482","version":"1","preferredName":"Oxybutynin 5.0 mL","longName":"7634482","preferredDefinition":"Oxybutynin 5.0 mL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFF0F9C2-F5CC-4F5A-E053-4EBD850A6491","latestVersionIndicator":"Yes","beginDate":"2021-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFF0F9C2-F5E5-4F5A-E053-4EBD850A6491","beginDate":"2021-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","deletedIndicator":"No"},{"value":"Oxybutynin 2.5 mL","valueDescription":"Oxybutynin 2.5 mL","ValueMeaning":{"publicId":"7634483","version":"1","preferredName":"Oxybutynin 2.5 mL","longName":"7634483","preferredDefinition":"Oxybutynin 2.5 mL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFF0F9C2-F5EF-4F5A-E053-4EBD850A6491","latestVersionIndicator":"Yes","beginDate":"2021-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFF0F9C2-F608-4F5A-E053-4EBD850A6491","beginDate":"2021-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-14","modifiedBy":"ONEDATA","dateModified":"2021-04-14","deletedIndicator":"No"},{"value":"Arm B: Avelumab + Cabozantinib","valueDescription":"Arm B: Avelumab + Cabozantinib","ValueMeaning":{"publicId":"8012239","version":"1","preferredName":"Arm B: Avelumab + Cabozantinib","longName":"8012239","preferredDefinition":"Arm B: Avelumab + Cabozantinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D655D7E2-E33A-6899-E053-4EBD850A8AC0","latestVersionIndicator":"Yes","beginDate":"2022-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-24","modifiedBy":"ONEDATA","dateModified":"2022-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D655D7E2-E353-6899-E053-4EBD850A8AC0","beginDate":"2022-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-24","modifiedBy":"ONEDATA","dateModified":"2022-01-24","deletedIndicator":"No"},{"value":"Arm A: Avelumab","valueDescription":"Arm A: Avelumab","ValueMeaning":{"publicId":"8012240","version":"1","preferredName":"Arm A: Avelumab","longName":"8012240","preferredDefinition":"Arm A: Avelumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D655D7E2-E35D-6899-E053-4EBD850A8AC0","latestVersionIndicator":"Yes","beginDate":"2022-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-24","modifiedBy":"ONEDATA","dateModified":"2022-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D655D7E2-E376-6899-E053-4EBD850A8AC0","beginDate":"2022-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-24","modifiedBy":"ONEDATA","dateModified":"2022-01-24","deletedIndicator":"No"},{"value":"Arm 2: Dose Adjusted Hyper-CVAD","valueDescription":"Arm 2: Dose Adjusted Hyper-CVAD","ValueMeaning":{"publicId":"8024702","version":"1","preferredName":"Arm 2: Dose Adjusted Hyper-CVAD","longName":"8024702","preferredDefinition":"Arm 2: Dose Adjusted Hyper-CVAD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D70996A9-64F2-702E-E053-4EBD850AD4CE","latestVersionIndicator":"Yes","beginDate":"2022-02-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-02-02","modifiedBy":"ONEDATA","dateModified":"2022-02-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D70996A9-650B-702E-E053-4EBD850AD4CE","beginDate":"2022-02-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-02-02","modifiedBy":"ONEDATA","dateModified":"2022-02-02","deletedIndicator":"No"},{"value":"Arm 1: Inotuzumab ozogamicin + mini-hyper-CVD","valueDescription":"Arm 1: Inotuzumab ozogamicin + mini-hyper-CVD","ValueMeaning":{"publicId":"8024703","version":"1","preferredName":"Arm 1: Inotuzumab ozogamicin + mini-hyper-CVD","longName":"8024703","preferredDefinition":"Arm 1: Inotuzumab ozogamicin + mini-hyper-CVD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D70996A9-6515-702E-E053-4EBD850AD4CE","latestVersionIndicator":"Yes","beginDate":"2022-02-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-02-02","modifiedBy":"ONEDATA","dateModified":"2022-02-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D70996A9-652E-702E-E053-4EBD850AD4CE","beginDate":"2022-02-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-02-02","modifiedBy":"ONEDATA","dateModified":"2022-02-02","deletedIndicator":"No"},{"value":"Part 2 (MTD)","valueDescription":null,"ValueMeaning":{"publicId":"10485133","version":"1","preferredName":"Part 2 (MTD)","longName":"10485133v1.00","preferredDefinition":"Part 2 (MTD)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E181261B-7CB4-494B-E053-731AD00A555E","latestVersionIndicator":"Yes","beginDate":"2022-06-16","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-06-16","modifiedBy":"ZHWENDY","dateModified":"2022-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E181261B-7CB5-494B-E053-731AD00A555E","beginDate":"2022-06-16","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-06-16","modifiedBy":"ZHWENDY","dateModified":"2022-06-16","deletedIndicator":"No"},{"value":"Part 2 (Expansion)","valueDescription":null,"ValueMeaning":{"publicId":"10485134","version":"1","preferredName":"Part 2 (Expansion)","longName":"10485134v1.00","preferredDefinition":"Part 2 (Expansion)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E17EB6C1-E4F4-496F-E053-731AD00AED03","latestVersionIndicator":"Yes","beginDate":"2022-06-16","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-06-16","modifiedBy":"ZHWENDY","dateModified":"2022-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E17EB6C1-E4F5-496F-E053-731AD00AED03","beginDate":"2022-06-16","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-06-16","modifiedBy":"ZHWENDY","dateModified":"2022-06-16","deletedIndicator":"No"},{"value":"Trabectedin","valueDescription":null,"ValueMeaning":{"publicId":"3380231","version":"1","preferredName":"Trabectedin","longName":"3380231","preferredDefinition":"A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trabectedin","conceptCode":"C1691","definition":"A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-15DE-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Yondelis as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5FB201E-B92C-6100-E053-731AD00AC957","beginDate":"2022-08-11","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-08-11","modifiedBy":"CLOHNES","dateModified":"2022-08-11","deletedIndicator":"No"},{"value":"Pazopanib","valueDescription":null,"ValueMeaning":{"publicId":"3380355","version":"1","preferredName":"Pazopanib","longName":"3380355","preferredDefinition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pazopanib","conceptCode":"C74547","definition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A6CA-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5FB201E-B92D-6100-E053-731AD00AC957","beginDate":"2022-08-11","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-08-11","modifiedBy":"CLOHNES","dateModified":"2022-08-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB82EBDA-7F98-3460-E053-4EBD850A1FCF","latestVersionIndicator":"Yes","beginDate":"2004-06-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"CLOHNES","dateModified":"2022-08-11","changeDescription":"2-1-22 TL received permission from BC to add 2 PVs. 1-24-22 TL received permission from BC to add 2 PVs. 7-28-20 TL versioned to 1.1 for changes to 2 PVs/BC. 6-30-20 tmt added 2 PVs for EAQ191/BC.","administrativeNotes":"8/11/22 added 2 PVs of Trabectedin and Pazopanib per AK CJL;","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Which arm has the patient bee","type":"Preferred Question Text","description":"Which arm has the patient been randomized to on GOG-0252?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Which treatment regimen will the patient be receiving?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"If the patient is randomized to the control arm, what is the planned treatment regimen?","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB8224B8-8AEC-5363-E053-4EBD850A543F","latestVersionIndicator":"Yes","beginDate":"2011-02-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-28","modifiedBy":"TAYLORT","dateModified":"2020-07-28","changeDescription":"7-28-20 CDE versioned to 2.0 per VD v1.1; TL/BC.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}